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CHAPTER 1. INTRODUCTION 
1.1  Human kinome and protein kinase domain 
1.1.1 Protein kinases 
Protein kinases are the enzymes that catalyze protein phosphorylation, one 
of the most important protein post-translational modifications (PTMs), by 
transferring a phosphate group from the nucleotide molecules (e.g., Adenosine 
triphosphate (ATP)) to the substrate proteins (Fontana & Lovenberg, 1973; 
Guidotti, Kurosawa, Chuang, & Costa, 1975; Insel, Bourne, Coffino, & Tomkins, 
1975). Protein phosphorylation is critical to activate or deactivate protein functions: 
by adding a phosphate group, the protein conformation is altered, subsequently, 
the protein switches to “on” or “off” states that may enhance or reduce downstream 
cell signaling (Burnett & Kennedy, 1954; Cohen, 1982; O'Connor, Gard, & 
Lazarides, 1981). Since protein phosphorylation is highly regulated by kinases, 
protein kinases play critical roles in mediating multiple biological processes and 
molecular functions, such as cell proliferation (Aithal, Toback, & Cryst, 1980; Cerda 
et al., 2006; Kuninaka et al., 2007; Pelaia et al., 2007), apoptosis (Gabai, Mabuchi, 
Mosser, & Sherman, 2002; Otani, Erdos, & Leonard, 1993) and protein 
degradation (Cazarin, Andrade, & Carvalho, 2014; Lu et al., 1998; Mizuguchi et al., 
1988; Tai et al., 2017). Importantly, deregulation of protein kinases may induce 
impaired cellular pathways and signal transduction, such as Wnt pathway (Ehyai 
et al., 2015; Ohishi et al., 2015) and  insulin signaling pathway (Numata et al., 2011; 
Ohta et al., 2015; Sawada, Yamashita, Zhang, Nakagawa, & Ashida, 2014; 
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Whelan, Dias, Thiruneelakantapillai, Lane, & Hart, 2010), which contributes to a 
variety of human diseases, such as cancer (ElMokh et al., 2017; M. Li et al., 2017), 
cardiovascular disease (Behr et al., 2003; Oudit et al., 2004) and type 2 diabetes 
(Kume et al., 2016; Russo, Russo, & Ungaro, 2013; Sidarala & Kowluru, 2016). 
1.1.2 The human kinome 
In 2002, Manning et al (Manning, Whyte, Martinez, Hunter, & Sudarsanam, 
2002), revealed a comprehensive discovery of protein kinase genes in human 
genome, where they reported 518 protein kinases in total (516 protein kinase 
based on their 2007 updates). The human kinome constitutes 1.7% of the human 
genes. Among the 518 protein kinases, 478 kinases have a “typical” eukaryotic 
catalytic domain, also known as  eukaryotic protein kinase (ePK), containing 12 
common subdomains which construct a highly conserved kinase catalytic core 
(Hanks & Hunter, 1995); meanwhile, there are 40 “atypical” protein kinase (aPK) 
which have the kinase activity but lack of the common eukaryotic catalytic domain 
(also known as the kinase core) (Manning et al., 2002). 
1.1.3 Importance of ePK and its classification 
Numerous studies have implied that typical ePKs are essential for normal 
cell signaling and responsible for pathogenesis of many human diseases. For 
example, RAC-alpha serine/threonine-protein kinase (Protein kinase B or AKT) is 
one of the very first discovered and extensively studied ePKs because AKT is able 
to phosphorylate a range of substrates which are in charge of various critical 
biological processes, such as cell growth, death and angiogenesis. In 1995, 
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Burgering, B. M et al. (Burgering & Coffer, 1995) reported that AKT is directly 
involved in phosphatidylinositol-3-OH kinase (PI3K) signaling cascade. During the 
past few decades, PI3K/AKT signaling have been proven to participate in many 
molecular functions and diseases (e.g., insulin signaling, diabetes, cancer, etc.); 
For example: a) Farrar, C et al. (Farrar, Houser, & Clarke, 2005) revealed that 
activation of PI3K/AKT pathway increased protein expression of insulin receptor 
by 200% in protein repair deficient mice, which suggested that AKT is a key 
regulator in insulin signaling pathway. b) A genetic study (Yin et al., 2017) showed 
a significant associate of AKT gene level and type 2 diabetes in Chinese population 
(248 T2D cases and 101 controls). c) Zhang, Y., et al. (Y. Zhang et al., 2017) 
conducted a large proteogenomic study across more than 11,000 cancer samples 
assigned to 32 cancer types (Figure 1-2), and they reported that multiple 
oncogenic mutation in PI3K/AKT pathway which has been demonstrated to be 
abnormal in multiple types of cancer.  
The 478 ePks have been classified into 8 groups:  
1. PKA, PKG, PKC families (AGC) (e.g., AKT);  
2. Calcium/calmodulin-dependent protein kinase (CAMK) (e.g., Mitogen-activated 
protein kinase 1);  
3. Casein kinase 1 (CK1);  
4. CDK, MAPK, GSK3, CLK families (CMGC) (e.g., Glycogen synthase kinase-3 
alpha, Mitogen-activated protein kinase 8 or JNK1);  
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5. Homologs of yeast Sterile 7, Sterile 11, Sterile 20 kinases (STE) (e.g., Dual 
specificity mitogen-activated protein kinase kinase 1);  
6. Tyrosine kinase (TK) (e.g., insulin receptor, Tyrosine-protein kinase Fyn);  
7. Tyrosine kinase–like (TKL) (e.g., Serine/threonine-protein kinase B-raf);  
8. Other kinase (Other) that contains eukaryotic catalytic domain but does not 
belong to any groups above.  
The classification of typical ePKs was summarized in Table 1-1 (data source 
from (Manning et al., 2002), reformatted table).  As can be seen from Table 1, the 
tyrosine kinase (TK) group comprised 90 kinases is the largest group; AGC, CAMK 
and CMGC groups contain moderate number of kinases (63, 74, and 61, 
respectively); STE, TKL and CK1 are in the lower end of the kinome (47, 43, and 
12, respectively); Other group consists of relatively large number of kinases (83), 
which also play key roles in cellular functions and signal transduction, such as 
mitotic cell cycle progression regulated by serine/threonine-protein kinase Nek7 
(Yissachar, Salem, Tennenbaum, & Motro, 2006). 
1.1.4 aPKs also play critical roles 
Forty atypical protein kinases have been categorized into 8 groups: PDHK, 
Alpha, RIO, ABC1, BRD, PIKK, Other, and A6 (A6 was excluded from the most up 
to date kinome database). The best well-studied aPK might be mammalian target 
of rapamycin kinase (mTOR), which directly or indirectly regulates numerous cell 
signaling pathways including PI3K/AKT pathway (Amin et al., 2008; Babchia, 
Calipel, Mouriaux, Faussat, & Mascarelli, 2010; H. Zhang et al., 2007), MAPK 
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signaling pathway (Aldonza et al., 2015; Dormond-Meuwly et al., 2011; Landau et 
al., 2009), JNK signaling pathway (A. Kim et al., 2017; March & Winton, 2011; 
Shanware et al., 2014). As an atypical protein kinase, mTOR does not contains a 
classic kinase core as ePKs; however, mTOR has two distinct complexes, 
mTORC1 (Raptor) and mTORC2 (Rictor), which exhibit different molecular 
functions (Lipton & Sahin, 2014).  Nissim Hay et al.,(Hay & Sonenberg, 2004) 
reported that mTORC1 enhanced the protein synthesis by phosphorylating 
number of downstream transcription factors and ribosome kinases (e.g., 
Ribosomal protein S6 kinase beta-1), and AKT, a downstream effector of insulin 
receptor (IR)/insulin receptor (IRS)/PI3K pathway, was also a key mediator of 
mTORC1 (Figure 1-3); however, the mTORC2, as Sarbassov et al., (Sarbassov, 
Guertin, Ali, & Sabatini, 2005) described, could be an essential component to 
phosphorylate Akt on Ser473, which demonstrated completely different cellular 
activity from mTORC1 (Figure 1-4). Hence, although the aPKs lack of a typical 
kinase core, they still exhibit strong regulatory impact on the cellular signal 
transduction.  
1.1.5 Other kinases (non-protein kinases)  
Beyond the 518 protein kinases in human, there are also many other non-
protein kinases of which the three main classes (sugar kinase, nucleoside kinase 
and liquid kinase) are discussed in this chapter. Far less researchers focus on non-
protein kinases (Maeda et al., 2006); however, some kinases in this category also 
play critical roles in cell signaling, such as PI3K.  
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1.1.5.1 Sugar kinases 
Sugar kinases mainly control aerobic glycolysis which generates critical 
energy for tumor cells, so minimizing the catalytic activities of these kinases (e.g., 
6-phosphofructo-2-kinase) could potentially inhibit the tumor growth (Chesney, 
Clark, Lanceta, Trent, & Telang, 2015). The sugar kinases can be categorized into 
4 groups: Hexokinases (HK), Ketohexokinases (KHK), 6-phosphofructo-2-kinase 
(PFK2) and Galactokinase.  
1.1.5.2 Nucleoside kinases 
Nucleoside kinases catalyze the phosphorylation on 5’- hydroxyl group on 
ribonucleosides, and they have been widely recognized playing important roles in 
NAD salvage pathway (T. Zhang et al., 2009); however, their molecular functions 
have not been fully understood. One of the well-studied nucleoside kinases, 
adenosine kinase 1 (AK1), transfers the gamma-phosphate from a molecule of 
ATP to adenosine resulting in a molecule of adenosine monophosphate (AMP). 
AK1 is the key mediator to maintain the cellular energy homeostasis, and Amiri, 
M., et al. (Amiri, Conserva, Panayiotou, Karlsson, & Solaroli, 2013) discovered that 
AK9 also exhibits nucleoside diphosphate kinase activity.  
1.1.5.3 Lipid kinases 
Lipid kinases mainly phosphorylate lipids by adding a phosphate group, and 
serve as important switches to “turn on and off” cell signaling. One of the best 
known lipid kinases, PI3K, phosphorylates phosphatidylinositol-4,5-bisphosphate 
(PIP2), to form phosphatidylinositol-3,4,5-trisphosphate (PIP3), which is a critical 
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mediator in response to stimuli (i.e., growth factor, insulin), subsequently, activates 
an extremely important downstream protein kinase, AKT (Guerrero-Zotano, Mayer, 
& Arteaga, 2016). PI3Ks are heterodimeric enzymes including catalytic subunits 
(p110) and regulatory subunits (p85), named based on their molecular weight. The 
p85 subunit recruits by receptor tyrosine kinases (RTKs) directly, then the p110 
subunit is activated by p85 resulting a fully functional PI3 kinase (Okkenhaug, 
2013). Figure 1-5 (Martini, De Santis, Braccini, Gulluni, & Hirsch, 2014) showed 
that the pathway initiated by RTK and PI3K involves in numerous crucial substrates 
proteins (i.e., Phosphoinositide-dependent kinase-1, AKT, mTORC1, ERK1/2).  
Hyper-activation and mutation of PI3K is very common in tumor cells and 
tissues where cell growth and proliferation are promoted whereas programmed cell 
death, apoptosis, is inactivated. Chen et al., (S. Chen et al., 2016) unveiled that 
inhibited PI3K activity reduced the colon cancer stem cell growth via decreased 
cell proliferation and increased cleaved caspase 3, which is a biomarker of cancer 
cell apoptosis.  
Hypoactive PI3K in diabetic animal or human models has been 
demonstrated. Supplement nutrition D-chiro-inositol (DCI), an essential secondary 
messenger in insulin signaling, was reported to significantly increase PI3K protein 
abundance in liver and skeletal muscle of diabetic rats, and resulting in reduced 
fasting plasma glucose and increased glycogen synthesis through PI3K/AKT 
pathway (Gao et al., 2016).  
1.1.6 Protein kinase catalytic core  
8 
 
 
 
Protein kinases, transferring a gamma-phosphate to substrate proteins and 
producing phosphorylated proteins, normally contain two types of domains, a 
highly conserved catalytic domain (kinase core) and a regulatory Src Homology 2 
(SH2) or a Src Homology 3 (SH3) domain. Proto-oncogene tyrosine-protein kinase 
(Src), for example, has regulatory domains SH2 and SH3, and a tyrosine kinase 
catalytic domain. The regulatory domains, acted as adaptors, allow the upstream 
signaling protein binding, which activates the tyrosine domain; subsequently, the 
active kinase core changed its conformation to allow ATP and substrate binding 
(Thomas & Brugge, 1997). However, as Kornev et al., described (Kornev, Haste, 
Taylor, & Eyck, 2006): not all the protein kinases have regulatory domains. cAMP-
dependent protein kinase (PKA), one of the first well characterized protein kinases, 
is a protein complex composed of catalytic subunits (i.e., PRKACA) and regulatory 
subunits.  For example, PRKACA only contains a kinase core which includes an 
N-terminal lobe (N-lobe) and a C-terminal lobe (C-lobe), and a cleft or hinge region 
located between the N-lobe and C-lobe. The docking cleft is for ATP binding. In 
Figure 1-6, upon PKA regulatory/activated protein binding, the subdomains of 
kinase core change their orientation and form an active conformation of PKA, 
which allows one molecule of ATP to specifically dock into the binding cleft.  
There are several highly conserved residues and motifs in the kinase core 
(C. Kim, Cheng, Saldanha, & Taylor, 2007). In the ATP binding cleft, N-lope forms 
a very hydrophobic pocket for ATP adenine ring, and glycine-rich loop (P-loop) 
forms a “lid” for three phosphate docking. One of the most important conserved 
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residues in the ATP binding pocket is the lysine in the N-lope (e.g., K72 in PKA), 
which stabilizes the alpha- and beta-phosphates in a low energy position in the 
binding domain. In the C-loop, there are two important motifs, Asp–Phe–Gly (DFG) 
motif and His–Arg–Asp (HRD) motif, which are highly conserved regions across 
all 478 ePKs. Another essential residue for exert catalytic activity is the aspartate 
(e.g., D184 in PKA) in the DFG motif, and D184 stabilizes the beta- and gamma-
phosphate through metal atoms, such as magnesium. DFG motif together with the 
following two residues form a “magnesium-binding” loop that is also highly 
conserved in the kinase core. DFG motif has two conformations, “DFG-in” and 
“DFG-out”, where “DFG-in” is an active conformation that allows to form the 
magnesium-binding loop while “DFG-out” is inactive conformation that hides the 
conserved aspartate in the deep hydrophobic region prevents the three ATP 
phosphates from binding to the cleft between N-lope and C-lope (Vijayan et al., 
2015). Therefore, inactive conformation of the kinase core (specifically DFG-out) 
might hinge ATP binding. One example of taking advantage of the conserved DFG 
motif: imatinib (Gleevec), one of most successful type II tyrosine kinase inhibitors 
treating chronic myelogenous leukemia, favors the DFG-out conformation to keep 
it from active (Figure 1-7) (Treiber & Shah, 2013).  Another highly conserved motif 
in the kinase core is HRD motif which contains the aspartate (Asp166 in PKA) 
responsible for correcting orientation of substrate peptides. The 2nd residue which 
is apart from the aspartate in HRD motif to the C-terminal is another conserved 
lysine (Lys168 in PKA, Figure 1-6), which directly interacts with gamma-phosphate 
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in the ATP, and stabilizes the ATP binding. It plays a critical role in the gamma-
phosphate transferring.  
Mitogen-activated protein kinase 1 (MAPK1 or ERK2) is a key functional 
protein kinase in MAP kinase pathway, which has been known involving in 
numerous biological processes (e.g., cell growth (Husain et al., 2001) and 
apoptosis (Zhou et al., 2015)) and pathogenesis of human diseases (e.g., cancer 
(X. W. Li, Tuergan, & Abulizi, 2015) and diabetes (Kinoshita et al., 2011)). MAPK1 
has very similar kinase core as PKA demonstrated above, and contains serval 
highly conserved residues: Lys54 in the N-lobe for ATP docking; Asp167 in DFG 
motif for activating MAPK1; Asp149 and Lys151 in the HRD catalytic motif for 
gamma-phosphate transferring (Figure 1-8).  
In summary, a) N-lobe and C-lobe are forming the kinase core which 
presents in all eukaryotic protein kinases; b) The cleft or hinge for ATP binding 
contains multiple highly conserved domains: glycine-rich loop (ATP binding), DFG 
motif (active or inactive conformation) and HRD (catalytic activity); c) Two lysine 
residues (e.g., Lys72 in N-lobe and Lys168 in C-lobe, PKA) are highly conserved, 
and stabilize and correct orientation of ATP binding. d) Active protein kinases very 
likely form a perfect ATP binding microenvironment, conducting a successful 
gamma phosphate transfer from ATP to substrate proteins.   
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Figure 1-1. The Protein Kinase Complement of the Human Genome (Human 
Kinome).  Figure adapted from G Manning et al., Science. 2002.  
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Figure 1-2. Diagram of somatic mutation and copy-number alteration (CNA) 
frequencies involving components of the PI3K/AKT/mTOR pathway. Figure 
adapted from Zhang et al., Cancer Cell, 2017.  
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Figure 1-3. The regulation mTORC1 activity by insulin through 
PI3K/AKT/mTOR pathway. Figure adapted from Hay, N. and N. Sonenberg, 
Genes Dev, 2004.  
 
 
 
 
Figure 1-4. The critical role of rictor-mTOR (mTORC2) in Akt/PKB activation 
Figure adapted from Sarbassov et al., Science, 2005.  
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Figure 1-5. Overview of PI3 kinase and Akt signaling pathway. Figure 
adapted from Martini et al., Ann Med, 2014.  
 
 
Figure 1-6. Diagram of known interactions between the protein kinase 
catalytic core, ATP and a substrate in PKA. Figure adapted from Kornev et al., 
PNAS, 2006. 
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Figure 1-7.  DFG-In and -Out conformations of inhibitor bound ABL. Figure 
adapted from Treiber, D. K. Shah, N. P. Chem Biol. 2013. (A) Type i tyrosine kinase 
inhibitor, VX-680, favors “DFG-in” conformation; (B) Type ii tyrosine kinase 
inhibitor, Imatinib, favors “DFG-out” conformation. 
 
 
 
 
Figure 1-8. Diagram of the inferred interactions between the human ERK2 
(MAPK1) kinase catalytic core residues, ATP, and the protein substrates. 
Figure adapted from Kornev et al., PNAS, 2006. 
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Table 1-1 Classification of eukaryotic protein kinases (ePKs) 
Group  Symbols Number of kinases  
Containing PKA, PKG, PKC families  AGC 63 
Calcium/calmodulin-dependent protein kinase  CAMK 74 
Casein kinase 1 CK1 12 
Containing CDK, MAPK, GSK3, CLK families  CMGC 61 
Homologs of yeast Sterile 7, Sterile 11, 
Sterile 20 kinases STE 47 
Tyrosine kinase  TK 90 
Tyrosine kinase–like TKL 43 
Other Other 83 
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1.2  Skeletal muscle insulin resistance in obesity and Type 2 diabetes 
1.2.1 Global epidemic: Obesity and Type 2 diabetes 
Obesity, defined as Body Mass Index ≥ 30 kg/m2, is one of the world 
epidemics: according to the datasheet from World Heath Organization (WHO), 
there were almost two billion adults are overweight (BMI≥ 25 kg/m2), and more 
than 600 million of these were obese in the world in 2014; what’s more, 41 million 
children (under age of 5) were overweight or obese in the same year. The 
population on the earth was 7.347 billion (World Bank, United States Census 
Bureau) in 2015, which means approximately 28% of the world population were 
overweight and 8.1% were obese. The prevalence of obesity in the United States 
is even worse, 70.7% of U.S. adults population were overweight (including obesity); 
more than one third (37.9%) U.S. adults were obese; 9.4% of children (age 2-5 
years) in the U.S. were obese in 2013-2014, as reported by Centers for Disease 
Control and Prevention (CDC). The trends of obesity prevalence in the U.S. has 
been substantially increased during the past few decades. In Figure 1-9, only 10-
14% U.S. adults suffered obesity in 1990 and this number increased to around 20% 
in 2000 (Figure 1-10); Surprisingly, the prevalence of obesity experienced rapid 
upsurge to more than 35% among U.S. adults in 2010 (Figure 1-11). Therefore, it 
is critical to prevent obesity and understand the cellular mechanism of obesity.  
Obesity is a known risk factor for many diseases, such as diabetes (X. M. 
Liu, Liu, Zhan, & He, 2015; Walsh & Vilaca, 2017), cardiovascular disease (X. M. 
Liu et al., 2015; Ortega, Lavie, & Blair, 2016; Rippe & Angelopoulos, 2016), and 
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some types of cancer (Cao & Giovannucci, 2016; Goodwin & Chlebowski, 2016; 
Nunez, Bauman, Egger, Sitas, & Nair-Shalliker, 2017). Importantly, insulin 
resistance has a strong correlation between obesity and type 2 diabetes (T2D) 
(Lackey & Olefsky, 2016; Wu & Ballantyne, 2017). Diabetes is a world burden that 
affects 422 million adults (age 18 years and above) global wide in 2014 (WHO 
facts report); critically, lower limb amputation rates are 10 to 20 times higher in the 
diabetic patients than normal population (Moxey et al., 2011). The global 
prevalence of diabetes is steadily increasing from 4.7% in 1980 to 8.5% in 2014. 
Similarly to the prevalence of obesity, the developed and rich countries, such as 
the United States, have higher diabetes rates than the world average. In 2012, 
National Health and Nutrition Examination Survey reported that 29.1 million people 
(i.e., 9.3% of U.S. population) had diabetes, and 8.1 million people with diabetes 
were not diagnosed. Importantly, approximately 95% of the diabetes were T2D 
(CDC reported in 2014), which has been often undiagnosed and underestimated; 
however, T2D may leads to a variety of serious medical complications (e.g., loss 
of vision, heart diseases, stroke, renal diseases, low limb amputations) (Acosta et 
al., 2000; Khalil, 2016; Papatheodorou, Papanas, Banach, Papazoglou, & 
Edmonds, 2016; Porte & Schwartz, 1996). Moreover, the number of U.S. adults 
with diagnosed diabetes has been increased from 5.1 million in 1980 to 21.3 million 
in 2012 (Figure 1-12); especially, the percentage of diabetic population located in 
the southeastern region of the U.S. has been elevated from 6.2% in 2000 to 15.2% 
in 2012 (Figure 1-13).  
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In summary, obesity and diabetes are global epidemics that affect a large 
portion of the human population; especially, the United States. Years of studies 
have demonstrated the clear link between insulin resistance, obesity, and type 2 
diabetes.  
1.2.2 Insulin resistance in skeletal muscle 
Food intake leads to the increase of plasma blood glucose.  In order to 
maintain the plasma glucose level, insulin is produced in the beta-cells of the 
pancreas and released to signal insulin sensitive tissues/organs to absorb 
excessive plasma glucose. Human skeletal muscle is responsible for 
approximately 75% of insulin-stimulated glucose uptake and is also the main site 
where insulin resistance takes place in obesity and T2D (Bjornholm & Zierath, 
2005; Zierath, Krook, & Wallberg-Henriksson, 2000). Using hyperinsulinemic 
euglycemic clamp technique (Diamond, Jacob, Connolly-Diamond, & DeFronzo, 
1993), researchers found that brain, splanchnic area, adipose tissues have similar 
insulin-stimulated glucose uptake in T2D patients  and non-diabetic controls; 
however, insulin-dependent glucose uptake in skeletal muscle tissue was 
dramatically reduced among T2D subjects (Figure 1-14). These results suggested 
that skeletal muscle resistance to insulin is a primary defect in T2D (DeFronzo, 
2004).  
1.2.3 Cellular mechanism of insulin resistance in skeletal muscle. 
1.2.3.1 Cellular mechanism of Normal Insulin Signaling  
20 
 
 
 
The principal pathways contributed to insulin resistance might be insulin 
signaling pathways activated by the insulin receptor, and one of the most 
extensively studied insulin signaling pathways is PI3K/AKT. The insulin signal 
transduction begins with ligand (insulin) binding to the insulin receptor (IR) which 
activates IR, a receptor tyrosine kinase. The activated IR phosphorylates insulin 
receptor substrate 1 (IRS1) and tyrosine phosphorylated IRS1 recruits PI3K, 
resulting in the activation of downstream kinases, such as AKT. Activated AKT 
induces glycogen synthesis via inhibition of glycogen synthase kinase 3 (GSK3); 
increases the glucose transporter type 4 (GLUT4) translocation to plasma 
membrane by blocking the activity of AKT substrate of 160 kDa (AS160); and 
promote the protein synthesis via activation of mammalian target of rapamycin 
complex (mTOR) pathway (Figure 1-15) (Prada & Saad, 2013; Puigserver et al., 
2003; Sano et al., 2003; Taniguchi, Emanuelli, & Kahn, 2006).  
1.2.3.2 Cellular mechanism of Insulin resistance in skeletal muscle 
The molecular mechanism of skeletal muscle insulin resistance remains 
unclear. In the IR-PI3K/AKT pathway, serval key regulatory protein kinases have 
been well investigated. Knocking out Akt2, for example, in mice has been reported 
to induce insulin resistance and metabolic syndrome (Cho, Mu, et al., 2001; Cho, 
Thorvaldsen, Chu, Feng, & Birnbaum, 2001); similarly, George S and colleagues 
(George et al., 2004), using genomic technique, revealed that a family with 
mutation in kinase domain of AKT2 led to impaired insulin sensitivity (insulin 
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resistance). These results implied that AKT2 is an essential modulator to 
phosphorylate downstream proteins in insulin signaling.   
IRS is an essential initiator in the upstream of insulin signaling. Figure 1-16 
(Copps & White, 2012) showed the pathway initiated by IRS and three tyrosine 
phosphorylation domains binding to p85 (subunit of PI3K), growth factor receptor-
bound protein 2 (GRB2) and SH2 domain-containing protein tyrosine 
phosphatase-2 (SHP2), and reduced tyrosine phosphorylation of IRS1 has been 
widely accepted (Copps & White, 2012) in insulin resistant states. In contrast, 
several studies showed that serine/threonine phosphorylation of IRS1 was 
significantly elevated in obese or T2D mice or rats, which suggests that increased 
serine/threonine phosphorylation of IRS1 may reduce its binding capacity to PI3K, 
and eventually inhibit AKT activity (Morino et al., 2005; Yu et al., 2002).  
1.2.4 Inflammation of skeletal muscle insulin resistance in obesity 
Skeletal muscle insulin resistance association with chronic inflammation 
has been widely recognized (Hotamisligil, 2006; Lumeng & Saltiel, 2011; McNelis 
& Olefsky, 2014; Osborn & Olefsky, 2012). Despite increasing evidence has 
implied that skeletal muscle inflammation occurs in obesity, the molecular 
mechanism is still not fully understood. Increased immune cells accumulating in 
myocytes of obese and T2D individuals has been reported (Fink et al., 2014; Fink 
et al., 2013; Khan et al., 2015; Patsouris et al., 2014; Varma et al., 2009), and high 
fat diet increased macrophage markers in insulin resistant obesity (Boon et al., 
2015; Tam et al., 2014). One theory of skeletal muscle insulin resistance 
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development is the activation of immune cells in the myocytes. For example, in 
figure 1-17, very few immune cells are resting in the skeletal muscle (panel A) in 
lean muscle, while macrophages and T cells, releasing cytokines, infiltrate into 
expand adipose depots (or called intermyocellular and perimuscular adipose 
tissue, IMAT) in obese skeletal muscle, which causes inflammation (panel B) (Wu 
& Ballantyne, 2017). The cytokines, including IFN-γ and TNF-α, can activate IκB 
kinase/NF-κB (IKK/NF-κB) and JNK pathways. Evidence showed that IKK/NF-κB 
pathway was elevated in obesity with T2D (Green, Pedersen, Pedersen, & Scheele, 
2011), and overexpression of IKK induced insulin resistance (Yuan et al., 2001). 
Furthermore, Hirosumi J and colleagues (Hirosumi et al., 2002) reported activated 
JNK pathway in obese individuals with insulin resistance; similarly, Chiang et al., 
(Chiang et al., 2009) indicated that JNK signaling was increased in obese mice. 
Therefore, in figure 1-18, cytokines activated signaling pathways, such as IKK/NF-
κB, SAPK/JNK and JAK/STAT, impaired insulin sensitivity might via reduced 
insulin-stimulated tyrosine phosphorylation and increased serine/threonine 
phosphorylation of IRS (Wu & Ballantyne, 2017).  
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Figure 1-9. Obesity trends among U.S. adults in 1990. Figure adapted from 
CDC.  
 
 
Figure 1-10. Obesity trends among U.S. adults in 2000. Figure adapted from 
CDC.  
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Figure 1-11. Obesity trends among U.S. adults in 2010. Figure adapted from 
CDC.  
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Figure 1-12. Number of US Adults Aged 18 or Older with Diagnosed Diabetes, 
1980-2012. Figure adapted from Diabetes Report Card 2014, CDC. 
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Figure 1-13. Geographic Distribution of Diagnosed Diabetes in the United 
States, 2000-2012. Figure adapted from Diabetes Report Card 2014, CDC. 
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Figure 1-14. Insulin-stimulated glucose uptake rates in various tissues in 
human. Figure adapted from DeFronzo, R. A. Med Clin North Am, 2004. 
 
 
Figure 1-15.  PI3K/AKT signal transduction pathway of insulin signaling. 
Figure adapted from Prada et al., Expert Opin Investig Drugs. 2013. 
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Figure 1-16.  Insulin signaling and feedback pathways initiated by IRS. Figure 
adapted from Copps, K. D. White, M. F. Diabetologia. 2012. 
 
 
 
 
 
 
Figure 1-17. Inflammation in skeletal muscle in obesity. Figure adapted from 
Wu, H. Ballantyne, C. M. J Clin Invest. 2017. 
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Figure 1-18. Inflammatory signaling mediates insulin resistance in myocytes 
via IRS/AKT pathway. Figure adapted from Wu, H. Ballantyne, C. M. J Clin Invest. 
2017. 
 
1.3 Activity-based kinome profiling  
Human kinome consists of more than 500 protein kinases which constitute 
1.7% of human genome, so high-throughput protein kinases enriching and profiling 
are highly demanded. Without kinome enrichment, traditional immunoblots 
technique (i.e., western blotting) requires to probe one kinase at a time with 
specific antibody against that kinase, and many kinases are not detectable due to 
the low protein abundance in the complex matrix (e.g., muscle tissue). Despite the 
immunoblotting is able to detect the protein kinases abundance, assessing the 
active form of kinase (i.e., certain serine/threonine or tyrosine phosphorylation of 
that kinase) might not be achievable due to lack of the phosphor-protein antibodies. 
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Therefore, activity-based ATP probes were developed for high-throughput 
enrichment of active protein kinases with the conserved kinase catalytic core, 
specifically, the 478 ePKs in human kinome.  
1.3.1 Kinase activity assay  
The traditional kinase function/activity assays (e.g., radiometric filtration 
binding assay, Figure 1-19) require radioisotope labeled ATP (H. Ma, Deacon, & 
Horiuchi, 2008), as well as specific substrate proteins which may not be 
commercially available. The enzyme activity is proportional for the utilized amount 
of ATP, calculating by initial ATP subtracted by the remaining ATP after the 
reaction. Other types of kinase functional assays are existing, such as 
fluorescence intensity assay, fluorescence polarization assay, scintillation 
proximity assay (von Ahsen & Bomer, 2005); yet, all the assays require prior 
knowledge on the kinase of interest and availability of corresponding substrates.   
1.3.2 Chemical structure and reaction of the activity-based probes 
Quantitative proteomics is primarily used to assess protein abundance in 
the cells or tissues; however, it becomes possible to detect proteins (enzymes) 
activities by coupling with activity-based enzyme enrichment. In 1999, Yongsheng 
Liu et al., (Y. Liu, Patricelli, & Cravatt, 1999) first synthesized the activity-based 
chemical probes for serine hydrolases enrichment of which a biotinylated 
fluorophosphonate (FP-biotin) was designed specifically for the active sites of 
serine hydrolases (Figure 1-20). Researchers developed various activity-based 
probe to assess enzyme activities (Bogyo, Verhelst, Bellingard-Dubouchaud, Toba, 
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& Greenbaum, 2000; Greenbaum et al., 2002; Okerberg et al., 2005; Saghatelian, 
Jessani, Joseph, Humphrey, & Cravatt, 2004).  
In 2007, the same research group (Patricelli et al., 2007) synthesized novel 
nucleotide acyl phosphates probes (also called kinase probes) that selectively bind 
to ATP binding pocket (in the kinase core) of eukaryotic protein kinases (Figure 1-
21). The kinase probes are constituted by an ATP group (adenosine ring and three 
phosphates) which selectivity binds to the ATP binding cleft, an acyl phosphate 
reaction group that forms an irreversible covalent bond with the conserved lysine, 
and a six carbon linker with a biotin tag which can be pulled down by the biotin 
affinity agarose beads (Avidin or Streptavidin). When the active-site directed 
probes bind to the active kinases, the conserved lysine residues can be labeled 
with biotin tags; subsequently, the labeled active kinases were digested by trypsin 
(a digest enzyme that cleaves specifically on lysine and arginine residues), and 
biotin tagged peptides of active kinases were enriched and analyzed by mass 
spectrometry. Figure 1-22 indicated two conserved lysine residues which are 
closed to the three phosphate groups in the ATP probe: one is K33 which is the 
conserved lysine on the N-lobe to stabilize the orientation of alpha- and beta-
phosphates, and the other is K129 which is located at the catalytic loop (2nd residue 
from HRD motif) and is key residue to transfer the gamma-phosphate to substrate 
peptides. Both lysine residues are highly conserved in nearly all the ePKs. 
Furthermore, the authors identified 3 conserved motif for kinase probe binding 
(Figure 1-23), where the size of the letter in given position represented the 
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proportion of that residue in the sequence; generally, bigger size of the letter the 
higher degree of conservation. A1 panel represented the conserved lysine in N-
lobe, and A2 & A3 panel showed the lysine in catalytic loop.  
Since the discovery of the activity-based kinase profiling, increased studies 
adopted this technique coupled with proteomics to perform kinase functional assay 
at large scale. Patricelli, M.P. and colleagues (Patricelli et al., 2011) revealed 
functional proteome of more than 200 native kinases against several well studied 
kinase inhibitors. Using activity-base kinase probe, recently, Okerberg et al., 
(Okerberg et al., 2016) identified a novel tumor-specific active site of casein kinase 
1α (CSNK1A1). Figure 1-24 showed peptide sequence of active site of CSNK1A1 
(panel A) and ion intensity of the mutated active site of CSNK1A1 (panel B).  
In summary, activity-based protein profiling selectively targets active site of 
protein kinases, which allows for studying functional kinome in biological matrix. 
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Figure 1-19. Diagram of radiometric filtration binding assay. Figure adapted 
from http://www.perkinelmer.com. 
 
Figure 1-20. Route for the synthesis of FP-biotin. Figure adapted from Liu et 
al., PNAS. 1999. 
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Figure 1-21. Structure and mechanism of kinase probes. Figure adapted from 
Patricelli et al., Biochemistry. 2007. 
 
 
 
Figure 1-22. Conserved lysine residues in Cyclin-dependent kinase 2. Figure 
adapted from Patricelli et al., Biochemistry. 2007. 
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Figure 1-23. Three highly conserved kinase probe binding motifs. (A1) ATP 
binding site motif; (A2) Catalytic binding motif 1; (A3) Catalytic binding motif 2. 
Figure adapted from Patricelli et al., Biochemistry. 2007. 
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Figure 1-24. Analysis of a CSNK1A1 active-site peptide in both colon tumor 
and matched control samples. Figure adapted from Okerberg et al., PLoS One. 
2016. 
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1.4  Mass spectrometry-based quantitative proteomics  
Proteome represents complete set of proteins in organisms. Proteomics is 
a technique, coupled with biology and mass spectrometry (MS), to identify and 
quantify as many proteins as possible in organisms. Even though around 20,000 
genes in human genome has been sequenced, how many proteins (est. 1,000,000) 
and protein post-translational modifications in human remains unknown (Figure 1-
25) (Mayne et al., 2016). 
1.4.1 Protein immunoblotting versus MS-blotting  
Protein immunoblotting (i.e., Western blotting) is one of the most commonly 
used methods to assess protein abundance in biological matrix (S. F. Smith, 1989). 
Western blotting starts with separating the protein mixture in SDS-PAGE system 
based on their molecular weights, followed by primary antibody probing of the 
target protein. Using secondary antibody (against the primary antibody) and 
chemical substrate of the secondary antibody, the target protein can be visualized 
by colorimetric detection or fluorescent detection. This approach has been used 
as a fundamental method to study protein abundance and other properties in 
biology, biochemistry, pathology, etc. Western blotting has numerous advantage 
over other methods, for example, providing specific and accurate assessment of 
target protein abundance in complex biological samples (Lustbader & Pollak, 
1991). However, immunoblotting techniques are highly dependent on primary 
antibody; as a result, low quality antibody or lack of specific antibody for bait protein 
are limiting this method from high-throughput protein detection.  
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For many years, genomics has been primarily used for high-throughput 
gene mutation and sequencing study because methods for measuring proteins and 
metabolites could not achieve the high-throughput and in-depth as genomics 
techniques. However, quantitative proteomics started to provide global profiling of 
thousands of proteins in few hours. In 2015, Richards et al., reported that a one-
hour MS run could identify more than 4,000 proteins in yeast (Richards et al., 2015). 
The typical workflow for quantitative proteomics adapted the similar concepts of 
protein immunoblotting. The first step is separating the proteins (or peptides) 
mixture in high-performance liquid chromatography instruments (HPLCs). Second 
step is to analyze the extremely accurate molecular weight of each protein or 
peptides in a high resolution mass spectrometer (i.e., Oribtrap (Makarov, 2000)). 
The last step is to search the mass spectra against the known databases 
containing protein sequencing information (e.g., Uniprot). The protein abundance 
usually need to be normalized by internal or external standards. One of the biggest 
advantage of quantitative proteomics is that no specific antibody is required to 
identify the target proteins, and it can identify and quantify hundreds/thousands of 
proteins, protein phosphorylation and other post-translational modifications 
(PTMs). 
Another crucial application for quantitative proteomics (also known as MS-
blotting) is that MS-blotting could be applied for protein-protein interaction studies. 
In figure 1-26, we compared the advantages of MS blotting over the traditional 
immunoblotting.  For the western blotting, bait protein and partner protein need to 
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be probed separately; however, both bait and partner proteins can be identified by 
MS-blotting simultaneously because MS doesn’t require antibody probing. What’s 
more, in the protein-protein interaction experiments, the MS based method can 
detect hundreds of protein interaction partners, and identify novel partners that 
have not been found by the immunoblotting (Caruso et al., 2015).  
1.4.2 “Bottom-up” proteomics  
Today, proteomics is a powerful tool to profile comprehensive proteomes in 
various biological samples (e.g., cells, tissues, blood, etc.) (Cheung & Juan, 2017; 
W. Liu et al., 2017; Tsolis & Economou, 2017). Two basic classes of proteomics 
analysis are commonly employed to system biology: “Top down” and “bottom-up” 
proteomics where “top-down” means to analyze the intact proteins directly by MS 
whereas “bottom-up” refers that proteins are first digested by specific protease 
(e.g., trypsin), and the resulting peptides are analyzed by MS (Gregorich, Chang, 
& Ge, 2014). The main defect of “Top-down” proteomics is that large protein 
molecules are difficult to be separated, fractionated, and ionized.  Therefore, “Top-
down” proteomics is not commonly used for large scale profiling. In contrast, 
“bottom-up” approach generates the relatively small peptides which can be easily 
separated and analyzed by MS, and the raw MS files containing the peptides 
information can be mapped and assigned to protein based on protein sequencing 
databases; hence, “bottom-up” proteomics is a primary proteomics method for 
high-throughput protein or/and PTMs profiling. For instance, Sacco, F. and 
colleagues were able to map 8,000 proteins and more than 16,000 
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phosphoproteins in breast cancer cells using “bottom-up” proteomics (Sacco et al., 
2016).   
1.4.3 “SILAC” based quantitative proteomics 
Stable isotope labeled amino acid in cell culture (also known as SILAC) has 
been widely used for quantitative proteomics (Doherty, Hammond, Clague, 
Gaskell, & Beynon, 2009; Duan, Kelsen, Clarkson, Ji, & Merali, 2010; 
Schwanhausser, Gossen, Dittmar, & Selbach, 2009). In 2002, Ong et al., first 
reported a SILAC method in which the two cell lines were cultured in two growth 
media containing two different isotopic labeled amino acids, the light (leu-d0) and 
heavy (leu-d3). Equal amount of the cell lysates from the light (leu-d0) and heavy 
(leu-d3) media were combined and analyzed together in one single MS-run (Figure 
1-27). Because of the high resolution mass spectrometer, light and heavy labeled 
peptides were differentiated and compared their ion intensity in one MS raw file. 
Proteins from the two different cell lines can be compared side by side, leading to 
reduced experimental error.   
In traditional SILAC experiments, up to three cell lines can be labeled and 
compared simultaneously, which is known as multiplex SILAC labeling. Seyfried 
et al., (Seyfried et al., 2010) reported to perform quantitative “SILAC” proteomics 
to enrich Sumolyation in three cell lines.  In order to apply this technique to the 
biological samples that are difficult to be labeled, such as tissue or plasma, a novel 
modified “SILAC” called super-SILAC was developed to explore the tissue based 
proteomics (T. Geiger, Cox, Ostasiewicz, Wisniewski, & Mann, 2010; Neubert & 
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Tempst, 2010; Pozniak & Geiger, 2014). Figure 1-28 is showing that the primary 
human skeletal muscle cells were labeled by 13C6 L-Arginine as heavy cells, and 
the skeletal muscle tissues were not labeled (non-labeled tissues were considered 
as light tissue). Then equal amount of heavy labeled cells was spiked into different 
light tissue samples, and the ratio of light/heavy of each sample was obtained. The 
relative quantification of the tissue samples was based on “ratio of ratio” 
comparisons. Using Super-SILAC, Noberini, R. and T. Bonaldi (Noberini & Bonaldi, 
2017) were able to largely profile histone post translational modifications in breast 
cancer tissues.  
In summary, super-SILAC based “bottom-up” proteomics is a promising 
approach to accurately identify and quantify proteome and post translation 
modification-proteome in complex biological tissue samples.  
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Figure 1-25. Schematic representation of the flow of bottom-up proteomics. 
Figure adapted from Mayne et al., Anal Chem. 2016. 
.  
 
 
Figure 1-26. Western blotting versus MS-blotting in the protein-protein 
interaction studies. 
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Figure 1-27. Diagram of SILAC labeling and workflow in MS. Figure adapted 
from Ong et al., Mol Cell Proteomics. 2002. 
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Figure 1-28. A schematic of Super-SILAC. Take 13C6 L-Arginine as an example. 
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CHARTER 2. HYPOTHESES, SPECIFIC AIMS AND 
EXPERIMENTAL DESIGN  
2.1 Hypotheses 
Although skeletal muscle insulin resistance is a primary contributor to the 
development of metabolic abnormalities and chronic diseases, such as type 2 
diabetes (T2D), the molecular mechanisms of its pathogenesis remain elusive 
(Abdul-Ghani & DeFronzo, 2009; Biddinger & Kahn, 2006; Cersosimo, MAndarino, 
& DeFronzo, 2011; DeFronzo & Abdul-Ghani, 2011; B. B. Kahn & Flier, 2000; 
Rask-Madsen & Kahn, 2012). A number of kinases, involved in insulin signaling, 
have been shown to have abnormal protein abundance and/or activity levels in 
insulin resistance (Taniguchi et al., 2006).  However, these studies are mainly 
performed in cell cultures or animal models, targeting only a limited number of 
known kinases.  The combination of kinase enrichment technologies with tandem 
mass spectrometry based proteomics offers a powerful approach for studying 
global profiles of kinases in human health and disease states.  However, no 
kinome profiling in insulin resistant skeletal muscle in humans have been reported 
so far.  We hypothesize that there are abnormal kinome and kinome 
inteactome profiles in skeletal muscle of insulin resistant human 
participants (OBi) as compared to insulin sensitive subjects (LC). The goal of 
the project is to identify novel kinase-based molecular mechanisms responsible for 
skeletal muscle insulin resistance in humans, providing new kinase targets for 
prevention and treatment of insulin resistance and T2D. 
2.2 Specific aims 
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Specific Aim 1: Assess differences in kinome profiles in skeletal 
muscle from lean healthy insulin sensitive (LC) and obese insulin resistant 
human participants (OBi).   
Specific Aim 2: Assess differences in kinome-interactome profiles in 
skeletal muscle from lean healthy insulin sensitive (LC) and obese insulin 
resistant human participants (OBi).  
2.3 Experimental design 
In figure 2-1, the two specific aims described in the overall experimental 
design flowchart demonstrate our research plan and strategy. Clinical studies were 
performed as we described (Caruso, Ma, Msallaty, Lewis, Seyoum, Al-janabi, 
Diamond, Abou-Samra, Højlund, et al., 2014). In brief, extensive subject 
recruitments were followed by comprehensive screening tests (e.g., oral glucose 
tolerance test (OGTT), body mass index (BMI), medical/health history, blood 
chemistry, ECG, etc.) at the clinical research center at Wayne State University. 
Eligible subjects underwent in-patient clinical tests: a 2 hour hyperinsulinemic-
euglycemic clamp to assess insulin sensitivity with muscle biopsies. Muscle biopsy 
was quickly cleaned of connective tissue and fat (~30sec). Biopsy was frozen in 
liquid nitrogen and was used for kinome/kinome interactome analysis by the 
Universal-SILAC approach developed in Dr. Yi’s laboratory (X. Zhang et al., 2014).  
Briefly, the study started with biopsy homogenization and spike-in standards 
(super-SILAC) to minimize experimental variation. The tissue and SILAC labeled 
cell lysate mixture was desalted by Zeba spin desalting columns to remove the 
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endogenous free ATP and salts in the lysis buffer. The desalted mixture lysate was 
labeled with ActivX ATP probes with desthiobiotin tag in the present of MgCl2, while, 
for the kinome interactiom study, half of the mixture lysate was not labeled with 
ATP probes. Those lysate without labeling was served as a negative control for 
eliminating non-specific binding.  
For specific aim 1, the labeled proteins were denatured by 8M urea buffer 
and subsequently reduced by dithiothreitol (breaking the disulfide bonds) and 
alkylated by iodoacetamide. The proteins were digested by MS-grade trypsin at 
37°C shaker overnight. The resulting tryptic peptides were pulled down by 
streptavidin agarose resin which has high affinity to desthiobiotin to enrich ATP 
probe labelled peptides (which were from active kinase since active kinases, but 
not inactive kinases, can be labelled by the ATP probe). The peptides pulled down 
were washed and eluted from the beads. Enriched ATP probe labelled peptides 
were desalted by C18 ziptip and analyzed by HPLC-ESI-MS/MS, followed by 
bioinformatics study using different databases (such as Ingenuity Pathway 
Analysis, Kyoto Encyclopedia of Genes and Genomes and Reactome pathway 
databases).  
For specific aim 2, double amount of tissue and cells as kinome 
enrichment in Aim 1 were homogenized. Then, half of the mixture (muscle and 
SILAC cells) lysate were labeled with ActivX ATP Probe whereas the other half 
won’t be labeled (serving as a negative control). Instead of trypsin digestion to 
generate labeled peptide, we will first pull down ATP probe labelled proteins (in 
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this case, active kinases, or active kinome) as well as their kinase interaction 
partners, or kinome interactome. Followed by IP lysis buffer washing, PBS washing 
and HPLC-grade water washing, three times of each, kinases and their binding 
partners were reduced and alkylated, then were digested by trypsin “on-beads” 
overnight. The tryptic peptides were desalted by C18 ziptip, followed by HPLC-ESI-
MS/MS analysis and bioinformatics study.  
 
 
 
 
Figure 2-1.  Schematic diagram of clinical, biological, and proteomics studies. 
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CHARTER 3. CLINICAL STUDY PROTOCOL AND 
CHARACTERIZATION OF HUMAN PARTICIPANTS 
3.1 Human participant recruitment and screening visit  
The participants for this project were recruited and studied at the clinical 
research center at the C.S. Mott Center for Human Growth and Development at 
Wayne State University. We started with initial phone screening to exclude any 
participants with significant diseases (i.e., cancer, type 1 diabetes, etc.) and inform 
the subjects study protocol of this clinical research, also schedule them for first on-
site visit (Visit 1).   
During the visit 1, we hired or collaborated with licensed research nurses 
(RN) and physicians who eventually determined the eligibility of participants and 
later perform muscle biopsy during visit 2. Participants were consented first with 
general introduction of our study and they had to sign the consent form which had 
been approved by Wayne State University IRB. We excluded participants based 
on our exclusion criteria, such as significant pulmonary diseases (e.g., COPD), 
heart diseases, diabetes coma, and extreme obese (BMI>40). Participants also 
had to pass the urine tests, ECG and routine blood tests. For example, participants 
with significantly lower than normal hemoglobin and hematocrit were excluded 
since they may have anemia that might cause bleeding problem during the muscle 
biopsy procedure (Barany, 2005; Ribeiro-Alves & Gordan, 2014; Torimoto & Kogo, 
2006).  
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For the non-diabetic participants, we had to conduct OGTT which is a test 
for diabetes diagnosis. Participants were fasting minimal 10 hours, and given 
glucose tolerance test beverages containing 75g glucose (Thermo Fisher Scientific, 
Inc) and we drew the blood every 30 minutes up to 2 hours for plasma glucose 
measurement using YSI 2300 glucose analyzer (Belfiore, Iannello, & Volpicelli, 
1998; Fujibayashi et al., 2015). We grouped the participants (non-diabetic, pre-
diabetic or diabetic) based on three criteria, HbA1C value, fasting glucose and 
blood glucose at 2 hours of the OGTT (Figure 3-1) (American Diabetes, 2012). 
Participants who meet at least one of the three criteria are considered as diabetes, 
a) A1C≥6.5; b) Fasting Plasma Glucose≥ 126mg/dl; c) 2h-Plasma 
glucose≥200mg/dl. 
3.2 Hyperinsulinemic-euglycemic clamp and muscle biopsies. 
The qualified participants were scheduled to the second visits for 
hyperinsulinemic-euglycemic clamp, the gold standard for insulin sensitivity 
measurement, and muscle biopsy. They had to be fasting at least 10 hours 
overnight and stop anticoagulants, which may cause bleeding, 7 days prior to the 
second visit. Hyperinsulinemic-euglycemic clamp was used to measure the insulin 
sensitivity of skeletal muscle in vivo (Cusi et al., 2000; DeFronzo, Tobin, & Andres, 
1979), as described in previous studies (Langlais et al., 2011; Yi et al., 2007). The 
study started at approximately 8:30 AM (time -60 minute point) in the morning and 
basal plasma glucose was measured. The blood was drawn through a catheter 
placed in an antecubital vein on one arm, which was covered by a heating pad 
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(60 °C), where we also infused saline to avoid dehydration. Another catheter was 
placed on the other arm for insulin and glucose infusion. The muscle biopsy was 
performed at -30 min with a percutaneous needle in vastus lateralis muscle of thigh 
under local anesthesia (use lidocaine). Muscle biopsies were immediately washed 
with ice-old saline containing proteases and phosphatases inhibitors, separated of 
connective tissue and adipose tissue then frozen in liquid nitrogen. At time 0 min 
point, we started the primed regular human insulin (Humulin R; Eli Lilly, 
Indianapolis, IN) infusion at constant rate 80 mU/m2/min and variably infuse 20% 
d-glucose to maintain the plasma glucose at 90 mg/dl. The theory of 
hyperinsulinemic-euglycemic clamp was described in Figure 3-2 that we 
continuously infused very high dose of insulin for 120 minutes to overcome the 
endogenous insulin effect and adjusted glucose infusion rate to target the plasma 
glucose at roughly 90 mg/dl by monitoring the blood glucose every 5 minutes. The 
average of glucose infusion rates during the last 30 minutes of the clamp (also 
known as M value, glucose uptake rate mg/kg.min) is widely used in the literature 
to represent the insulin sensitivity in skeletal muscle. The higher M value, the 
higher insulin sensitivity and the lower insulin resistance, vice versa (Caruso, Ma, 
Msallaty, Lewis, Seyoum, Al-janabi, Diamond, Abou-Samra, Hojlund, et al., 2014). 
In Figure 3-3, more than 200 participants who completed our clamp studies since 
2012 showed significantly different M-value between lean group and 
overweight/obese and T2D groups; however, no significant change of M-value was 
observed between overweight/obese and T2D group, which indicated that 
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overweight/obese and T2D participants were insulin resistant but lean group 
maintained normal insulin sensitivity.  
3.3 Clinical characterization the 16 participants recruited in kinome/kinome 
interactome study 
Totally, 8 lean healthy insulin sensitive and 8 obese insulin resistant 
participants were recruited this projects. In table 3-1, participants were matched 
with gender (5 males and 3 females in each group) and age (28.13 years old in 
lean group versus 33.00 years old in obese group, P>0.05). The BMI and 
percentage of body fat of these two groups showed significant difference where p-
value of BMI was less than 0.001 and p-value of % Fat Mass was less than 0.05 
(Figure 3-4); in contrast, their mean hemoglobin A1c % (HbA1c%), fasting blood 
sugar and 2h OGTT were similar and all were below the ADA’s prediabetes and 
T2D diagnosis cutoffs (Figure 3-5). OGTT was showed in Figure 3-6 where the 
plasma glucose of both groups reached a peak value (~130 mg/dL) and went down 
back to normal range at 2 hour time point, which means 8 lean and 8 obese 
subjects had normal glucose tolerance. In Figure 3-7, fasting plasma insulin levels 
were significantly elevated in obese insulin resistant subjects (p-value < 0.01), 
which implied the obese participants suffered from hyperinsulinemia. The lipid 
profiles were showed in Figure 3-8: A) the total cholesterol levels of obese 
participants were slightly increased but not significantly changed; (B) the 
triglycerides levels in insulin resistant obese participants were significantly 
elevated (p-value<0.05); (C) the high-density lipoprotein (HDL) cholesterol, which 
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may reduce the risk for cardiovascular disease and diabetes, was slightly but not 
significantly decreased in obese versus lean healthy participants (Bauer et al., 
2017; Rhee, Byrne, & Sung, 2017; Sanguinetti et al., 2001); (D) however, the low-
density lipoprotein (LDL) cholesterol, the known “bad” lipoproteins that could be an 
indicator for risk of cardiovascular disease (McCormack, Dent, & Blagden, 2016; 
Soltani et al., 2016) and has been observed to be elevated in obese and T2D 
participants (Marin et al., 2015), was significantly increased in the insulin 
resistance group compared to lean group (p-value < 0.05).  
As described above, the hyperinsulinemic-euglycemic clamp was applied 
to measure insulin sensitivity. The obese participants for the kinome project were 
selected based on their M-value, which is the key parameter reflected the insulin 
sensitivity, and we chose 8 obese participants with significantly low M-value and 
thus insulin resistance. Figure 3-9 is showing the infusion rate of glucose which 
compensated the high dose of insulin effect during the 120 minutes clamp. In the 
diagram, lean group reached a peak infusion rate of glucose and went down to 
stable stage while obese participants quickly reached to a much lower plateau than 
lean group without a peak dose of glucose. In figure 3-10, showing the M-value 
calculated based on the average of last 30 minutes glucose infusion rates, obese 
participants with insulin resistance had significantly lower M-value than lean 
healthy participants (p-value < 0.001).   
In summary, 8 lean healthy participants with normal glucose tolerance, 
insulin sensitivity, insulin and lipids, and 8 obese participants with normal glucose 
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tolerance but hyperinsulinemia and insulin resistance were enrolled in this 
kinome/kinome interaction partner study.  
 
Figure 3-1. The established glucose criteria for the diagnosis of diabetes. 
Figure adapted from American Diabetes Association (American Diabetes, 2012). 
 
 
 
. 
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Figure 3-2. Diagram of hyperinsulinemic-euglycemic clamp. Insulin infusion 
starts at time point 0 minute with constant rate, and adjusted rate of glucose 
infusion is to compensate the insulin effect. Plasma glucose was maintained at 
90mg/dL.  
 
 
 
Figure 3-3. Average M-value (mg/kg/min) of the participants completed clamp 
study.  M-value is indicating insulin sensitivity, and more than 200 subjects have 
completed hyperinsulinemic-euglycemic clamp in our study since 2011.  
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Figure 3-4. The BMI and percentage of body fat of the 8 lean and 8 obese 
participants. Bar charts are given as mean ± SEM. 
 
 
Figure 3-5. The HbA1c% and fasting glucose levels of the 8 lean and 8 
obese. Bar charts are given as mean ± SEM. 
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Figure 3-6. Oral glucose tolerance test (OGTT) of the 8 lean and 8 obese 
participants. Scatter plots are given as mean ± SEM. 
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Figure 3-7. Fast plasma insulin level in 8 lean and 8 obese participants. 
(A) The scatter plots are showing the individual fasting plasma insulin (pmol/L) of 
the 8 lean and 8 obese subjects. (B) The bar charts are representing the fasting 
plasma insulin (pmol/L) in mean ± SEM. 
 
 
 
 
 
Figure 3-8. Lipid profiles of the 8 lean and 8 obese subjects. Four panels 
represent: (A) total cholesterol; (B) Triglycerides; (C) HDL cholesterol; (D) LDL 
cholesterol. 
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Figure 3-9. Two-hour hyperinsulinemic-euglycemic clamp data points of the 
8 lean and 8 obese participants. The blue line represents lean group and orange 
line stands for obese group (scatter plots are given as mean ± SEM). 
 
 
 
Figure 3-10. M-value of the 8 lean and 8 obese subjects. 
(A) The scatter plots are showing the individual M-value (mg/kg/min) of the 8 lean 
and 8 obese subjects. (B) The bar charts are representing the M-value (mg/kg/min) 
in mean ± SEM. 
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Table 3-1. Clinical characteristics of the 8 lean and 8 obese participants.  
  Lean (n=8) Obese(n=8) 
Gender (M/F) 5/3 5/3 
Age (years) 28.13±3.06 33.00±4.71 
BMI at V2 (kg/m2) 22.74±0.68 32.26±1.50*** 
%Fat Mass 16.95±3.16 27.10±3.38* 
HbA1C (%) 5.00±0.11 5.33±0.14 
Fasting blood suger (md/dL) 87.34±1.04 93.33±2.19 
2h OGTT (mg/dL) 104.65±6.15 99.70±5.07 
M value (mg/kg/min) 10.22±0.79 5.50±0.44 
Fasting plasma insulin (pmol/L) 19.39±3.13 40.84±7.63** 
Tot Chol (mg/dL) 140.38±14.75 166.50±10.30 
Triglycerides (mg/dL) 48.50±14.27 89.63±14.57* 
HDL Chol (mg/dL) 60.25±5.77 47.50±3.44 
LDL Chol (mg/dL) 72.00±11.65 108.50±10.07* 
* p-value <0.05   
* *p-value <0.01   
* **p-value <0.001 
Data are given as mean ± SEM   
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CHARTER 4. HUMAN KINOME PROFILING IN SKELETAL 
MUSCLE INSULIN RESISTANCE  
4.1 Introduction 
Protein kinases are the key regulatory modules for variety of biological 
processes, such as insulin signaling pathway, glucose metabolism and 
inflammation pathways. Dysregulated protein kinases might induce impaired 
signal transduction and diseases (e.g., insulin resistance, T2D). As described 
above, typical protein kinases (or ePKs) have a core structure for catalytic activity, 
and taking MAPK1 as an example in Figure 4-1, the protein kinase core (shared 
by majority of typical protein kinases) contains: 1) a conserved lysine (K54), located 
in N-lobe, for alpha- and beta-phosphates of the ATP binding; 2) a Glycine rich-
loop (also known as phosphate-binding loop or P-loop) for ATP binding; 3) another 
conserved lysine (K151), located in catalytic loop, for gamma-phosphate binding; 4) 
a DFG motif which is important for kinase activity; 5) a HRD motif in the activation 
loop which is also regulating the kinase activity, where the aspartate (D149) is 
responsible for transferring the gamma-phosphate to substrate proteins. In Figure 
4-2 (O. Hantschel & Superti-Furga, 2004), tyrosine-protein kinase Lck (Lck) is an 
example for active conformation of protein kinase core where p-loop is in the “open” 
position and DFG motif is also in “DFG-in” conformation; in contrast, Proto-
oncogene tyrosine-protein kinase Src (Src) is demonstrating the inactive kinase 
core where p-loop is in “closed” position and DGF motif is in “DFG-out” 
conformation. The Lck and Src have very similar size (509 amino acids of Lck, 536 
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amino acids of Src), ATP binding site (K273 in Lck and K298 in Src), and active 
site (D364 in Lck, D389 in Src); thus, they shared very similar kinase core structure 
which represents the active and inactive forms of most protein kinases. 
The ActivX™ Desthiobiotin-ATP Probes, one type of the activity-based 
protein profiling probes, consist of 1) a molecule of ATP which can be selectively 
bound to the ATP binding cleft between the N-lobe and C-lobe; 2) an acyl 
phosphate contain reaction group which can form a covalent bound with the 
conserved lysine residues (either the one in ATP binding pocket or the one in 
catalytic loop); 3) A desthiobiotin-tag which can be pulled down by streptavidin 
(Figure 4-3).  
Skeletal muscle insulin resistance is one of the main defects in T2D, and 
the molecular mechanism of insulin resistance in human skeletal muscle has not 
been fully understood. We hypothesized that abnormalities in active protein 
kinases play key roles in insulin resistance. Therefore, we sought to globally enrich 
active protein kinases in human skeletal muscle insulin resistance, and discover 
the abnormalities of protein kinases may contribute to the cellular mechanism and 
pathogenesis of insulin resistance.  
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Figure 4-1. Protein kinase core of MAP kinase-1. (Figure adapted from Kornev 
et al., PNAS, 2006). 
 
Figure 4-2. Active and inactive protein kinase core.  
Lck represents active conformation whearas Src represents inactive conformation 
of kinase core. Figured adapted from Hantschel, O. Nature Reviews Molecular Cell 
Biology, 2004. 
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Figure 4-3. Chemical structure of the desthiobiotin-ATP probe. (Figure 
provided by the vendor). 
 
4.2 Materials and Methods 
4.2.1 Primary human skeletal muscle cells for SILAC labelling 
Ten to fifteen milligrams of freshly obtained human muscle biopsy were 
washed 3 times with ice cold Phosphate-Buffered Saline (PBS, pH 7.4, catalog # 
10010049, Invitrogen, Carlsbad, CA), and were transferred to a 100mm sterile cell 
culture dish. The muscle tissue was placed in the center of the dish using sterile 
forceps, and was minced finely using a small sterile scissors; subsequently, was 
transferred into a 50 mL conical centrifuge tube with 20 mL digestion solution (0.05% 
trypsin EDTA (catalog # 25200056, Invitrogen, Carlsbad, CA) in PBS). The tissue 
was incubated for 60 minutes at 37 °C, and the tube was swirled vigorously every 
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20 minutes. After the incubation, digested tissue pieces were centrifuged at 3000 
rpm for 15 minutes, and the pellet was transferred to a new 50 mL conical 
centrifuge tube with 10mL human skeletal muscle cells medium, where the based 
medium was Dulbecco's Modified Eagle's Medium with 1.0 g/L glucose (DMEM, 
catalog # 11885-092, Invitrogen, Carlsbad, CA) containing 20% Fetal Bovine 
Serum (FBS, catalog # SH3039603, Fisher scientific, Hampton, NH), 1% Penicillin-
Streptomycin-Glutamine (catalog # 10378-016, Invitrogen, Carlsbad, CA), 1% 
Non-essential Amino Acid (NEAA, catalog #11140-050, Lifetechnologies, 
Carlsbad, CA), 1% sodium pyruvate (catalog # 11360-070,  Lifetechnologies, 
Carlsbad, CA), 50 μg /mL fetuin (catalog # F2379-1G, Sigma, St. Louis, MO), 10 
ng/ML Epidermal growth factor (EGF, catalog # E5036-200UG, Sigma, St. Louis, 
MO), 0.4 μg /mL dexamethasone (catalog # D4902-100MG, Sigma, St. Louis, MO). 
The tissue was suspended and mixed 10 times with a 10mL pipette, following by 
removal of the undigested tissue using a sterile filter membrane. The filtrate 
containing myoblasts was plated in 100mm cell culture dishes, and primary 
cultured cells were maintained in a cell culture incubator (37 °C, 5% CO2). 
4.2.2 SILAC labeled skeletal muscle cells  
The primary cultured human skeletal muscle cells were sub-cultured in 
SILAC growth medium which labeled the cells with heavy isotopic amino acids 
(e.g., lysine, arginine), which are essential for cell growth. The SILAC growth 
medium included DMEM Media for SILAC (catalog # 88420, Thermo Fisher 
Scientific, Waltham, MA), 20% dialyzed FBS for SILAC (catalog # 88440, Thermo 
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Fisher Scientific, Waltham, MA), 0.1 mg/mL L-Lysine-2HCl, 4,4,5,5-D4 for SILAC 
(catalog # 88438, Thermo Fisher Scientific, Waltham, MA), 0.1 mg/mL L-Arginine-
HCl, 13C6, 15N4 for SILAC (catalog # 89990, Thermo Fisher Scientific, Waltham, 
MA), 1% Penicillin-Streptomycin-Glutamine (catalog # 10378-016, Invitrogen, 
Carlsbad, CA), 10 ng/ML Epidermal growth factor (EGF, catalog # E5036-200UG, 
Sigma, St. Louis, MO), 0.4 μg /mL dexamethasone (catalog # D4902-100MG, 
Sigma, St. Louis, MO). After 6 doublings of SILAC medium culture, the cells were 
collected by PBS. The cells were tested to be more than 95% labeled by lysine-4 
(4 Da heavier than neutral lysine) and arginine-10 (10 Da heavier than neutral 
arginine) using HPLC-ESI-MS/MS (Data not shown).  
4.2.3 Active protein kinase enrichment for functional kinome 
Approximately 60–80 mg frozen muscle biopsies from 8 lean control (LC) 
and 8 obese insulin resistance (OBi) participants, and mixed SILAC labeled 
skeletal muscle cells from 2 LC and 2 OBi subjects were homogenized using a 
Next Advance Bullet Blender (Model BBY5E) and lysed by Pierce IP Lysis Buffer 
(catalog # 87787, Thermo Fisher Scientific, Waltham, MA) with 8M urea (catalog 
# BP169-500, Fisher scientific, Hampton, NH) and Halt™ Protease/Phosphatase 
Inhibitor Cocktail (catalog # 78440, Thermo Fisher Scientific, Waltham, MA). 
Protein concentration was measured by Bradford protein assay, where Coomassie 
blue plus Kit with standard (catalog # PI-23236, Fisher scientific, Hampton, NH) 
was used for this assay. For each sample, 1.0 mg tissue lysate spiked-in with 0.5 
mg SILAC cell lysate (Four cell lines from 2 LC and 2 OBi were pooled first) was 
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aliquoted. Then the mixed lysate went through Zeba™ Spin Desalting Columns, 
7K MWCO, 5mL (catalog # 89891 Thermo Fisher Scientific, Waltham, MA) to 
remove all the endogenous ATP. The filtrate lysate of 8 LC and 8 OBi were diluted 
with reaction buffer (provided in Pierce™ Kinase Enrichment Kits, catalog # 88310, 
Thermo Fisher Scientific, Waltham, MA) into 2 mg/mL, and incubated with 10 μL 
of 1M MgCl2 at room temperature for 1 minute, followed by 10μM ActivX™ 
Desthiobiotin-ATP Probe (catalog # 88311, Thermo Fisher Scientific, Waltham, 
MA) incubation at room temperature for 10 minutes. The probe labeled lysate was 
diluted with 8M urea and underwent reduction (10mM dithiothreitol (DTT) 
incubation for 30 minutes at 55 °C) and alkylation (50mM iodoacetamide (IAA) 
incubation for 30min at room temperature in dark). Each sample was digested by 
30μg trypsin Protease MS Grade (catalog # PI90058, Fisher scientific, Hampton, 
NH) for 16 hours at 37°C. The resulting peptides were incubated with 50μL of 50% 
High Capacity Streptavidin Agarose resin slurry (catalog # 20357, Thermo Fisher 
Scientific, Waltham, MA) for 1 hour at room temperature on a mixing rotator; 
subsequently, the resin was washed 3 times with lysis buffer, 3 times with PBS, 
and 3 times with LCMS-grade water. The final enriched active protein kinase 
peptides were eluted 3 times with 75 μL Elution buffer (provided in Pierce™ Kinase 
Enrichment Kits). The eluted peptides were dried with a speedvac, and were 
reconstituted with 0.1% TFA in water (catalog # LS119 1, Fisher scientific, 
Hampton, NH) for HPLC-ESI-MS/MS.  
4.2.4 HPLC-ESI-MS/MS analysis 
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The active protein kinase peptides were isolated on a 75 μm ID and 400mm 
long C18 reversed phase analytical column which was in-house packed with 
ReproSil-Pur C18-AQ μm resin (Dr. Maisch GmbH). The HPLC (UltiMate 3000, 
Thermo Fisher Scientific, Waltham, MA) was equipped with two nano-flow UHPLC 
pumps (upper pressure limit 800 bar). A linear HPLC gradient, 2-35% phase B (0.1% 
FA in acetonitrile, catalog # LS120 1, Fisher scientific, Hampton, NH) was used to 
separate peptide mixture, where phase A was 0.1% FA in water (catalog # LS118 
1, Fisher scientific, Hampton, NH). The LTQ-Orbitrap Elite tandem mass 
spectrometer (Thermo Fisher Scientific, Waltham, MA) coupled with a nano flex 
electronic spray ion source was employed to analyze the isolated peptides.  
The parameters of nano-ESI was optimized to ionize peptides: spray 
voltage 2.0 kV, capillary temperature 200 °C, sheath/aux/sweep gas flow rate 0.  
The MS instrument parameters were setup for “bottom-up” proteomics: 1) A full 
survey scan 300-1650 Th was acquired using 240,000 resolution power at positive 
mode; 2) The top 20 most intense the ion peaks were selected for fragmentation 
(MS/MS) by collision-induced dissociation (CID) with 33.0 normalized collision 
energy and 1.0 m/z isolation window; 3) 30 seconds dynamic exclusion, a time 
window in which the same ions are not selected for MS/MS; 4) singly charged ions 
were excluded for MS/MS.  
 
4.2.5 Database search  
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The raw MS files generated from Xcalibur (Thermo Fisher Scientific, 
Waltham, MA) were searched against Uniprot human protein sequences 
(05/16/2014 version, www.uniprot.org) using MaxQuant software (verison.1.3.0.5) 
(Cox & Mann, 2008; Cox et al., 2009; Monetti, Nagaraj, Sharma, & Mann, 2011; 
Neuhauser, Michalski, Cox, & Mann, 2012). In the MaxQuant, besides the default 
variable modifications (Oxidized Methionine and acetylation at protein N-term), a 
novel variable modification, Desthiobiotin K, was manually added in the searching 
engine. The false discovery rate (FDR) for protein and peptides (at least 6 amino 
acid length) were both set at 1%; the Enzyme type chose “Trypsin”; multiplicity was 
set at 2 including light labels and heavy Arg10 & Lys4 labels; maximal 2 missed 
cleavages were allowed; the parent ion mass tolerance was 5 parts-per million 
(ppm) and fragment ion mass tolerance was 0.5 Da. The MaxQuant generated two 
main files, a desthiobiotin K peptides file (providing sequence of modified peptides 
with lysine sites and their intensity) and a protein group file (providing the kinase 
protein intensity).  
4.2.6 Active kinase lysine sites identification and quantification 
To be considered as an active kinase identified in the study, at least one of 
the two conserved lysine residues, one in the ATP-binding pocket and the other in 
the catalytic domain, of the active kinase lysine sites had to be enriched directly by 
the ATP-probe. To quantify and compare the active protein kinases between two 
groups, the enriched lysine sites have to meet the following three rigorous criteria: 
1) The localization probability of dethiobiotin modified lysine site must be greater 
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than 0.75; 2) either identified in at least half of the biopsy samples (i.e., ≥ 8 
samples), or identified only in at least half of biopsy samples of LC or OBi group 
(i.e., ≥ 4 samples); 3) for the kinases identified in both groups, a fold change of 
OBi/LC greater than 1.5 or less than 0.67 was required. The SILAC labeled heavy 
lysine sites identified in at least 8 out of 16 samples were used as “Universal” 
internal standard, and the total peak of the SILAC labeled lysine sites were 
calculated in each sample. Then, the peak area of each kinase (PAi) was 
normalized by the sum peak area of universal heavy labeled lysine sites in the 
same sample:  
Norm ∶  𝑖 =
PA𝑖
Total peak area of SILAC labeled lysine sites identified in ≥ 8 samples
 
The normalized protein kinase lysine site intensity underwent log 
transformation, and independent two-side t-test were employed to assess the 
significant changes (P<0.05) of active protein kinases in skeletal muscle between 
LC and OBi. For the kinases only identified in either LC or OBi, the fold changes 
of the kinases were assigned as infinity (Figure 4-4) and were considered as 
significant by default.  
4.2.7 Bioinformatics 
Pathway analysis of functional protein kinome were carried out by two 
software packages: 1) David bioinformatics (Huang da, Sherman, & Lempicki, 
2009; Huang et al., 2007) including variety of databases, such as Gene Ontology 
(GO) (Ashburner et al., 2000; Gene Ontology, 2015), Kyoto Encyclopedia of Genes 
and Genomes (KEGG) (Kanehisa & Goto, 2000; Ogata et al., 1999; Wixon & Kell, 
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2000), Rectome Pathway database (Croft et al., 2011) and PANTHER Pathway 
(Mi et al., 2017; Mi et al., 2005; Tang & Thomas, 2016); 2) Ingenuity Pathway 
Analysis (Ingenuity Systems, Redwood City, CA) whose database consists of the 
high quality knowledgebase of biological functions and molecular networks 
manually curated by scientists (Jimenez-Marin, Collado-Romero, Ramirez-Boo, 
Arce, & Garrido, 2009; Kramer, Green, Pollard, & Tugendreich, 2014). Due to the 
lack of “gold standard” for pathway analysis, multiple software packages might 
provide comprehensive analysis for functional kinome in skeletal muscle insulin 
resistance. 
4.3 Results 
4.3.1 Largest functional kinome in human skeletal muscle  
The desthiobiotin labelled lysine, K(de), of the identified protein kinases 
were manually searched using Uniprot database which provides the 
knowledgebase ATP binding lysine sites and the 2nd lysine site away from the HRD 
motif toward the C-terminal (in catalytic domain) (Patricelli et al., 2007). Only 
kinases identified with a desthiobiotin labelled known conserved lysine were 
considered as active protein kinases. The modified sequence of the active kinases 
showed high consistency with three known ATP probe binding motifs (Patricelli et 
al., 2007).  Totally, 71 active protein kinase lysine sites (assigned to 54 protein 
kinases) were identified in the kinome enrichment (Table 4-1). Seventeen of the 
54 kinases were enriched by both conserved lysine residues, and 7 out of the 54 
kinases were only bound to lysine residue in the ATP binding pocket while 34 
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kinases were only bound to the lysine residue located in the catalytic loop. 
Apparently, the protein kinases with lysine located in catalytic loop were more likely 
to be enriched by this desthiobiotin ATP probe. Since the reaction group on the 
probe is more likely to react with the gamma-phosphate which is located closer to 
the lysine in catalytic loop than the one in ATP binding site, it might be an 
explanation for why this activity based probe favors the lysine within the catalytic 
domain over the one in ATP binding site. Surprisingly, 53 of identified 54 protein 
kinases were serine/threonine kinases; only one tyrosine protein kinase, epidermal 
growth factor receptor (EGFR), was identified in this dataset. The reason could be 
the low abundance of tyrosine kinases which only comprises less than 20% of the 
total ePKs.  Additionally, as can be seen in Table 4-1, relatively large protein 
kinases can also be targeted; for example, microtubule-associated 
serine/threonine-protein kinase 2 (MAST2, sequence length: 1798 amino acids) 
was bound to the lysine in catalytic loop, and EGFR (sequence length: 1210 amino 
acids) was enriched on the lysine in the ATP binding site, which implied the high 
selectivity of the ATP probes that target the active conformation of protein kinases. 
In brief, we were able to identify 54 out of the total 478 ePKs (11%) in active 
conformation, which is largest functional kinome in human skeletal muscle insulin 
resistance to date.  
Canonical pathway analysis on the identified 54 kinases showed MAP 
kinase pathway, mTOR pathway, Insulin signaling pathway, JNK cascade, Wnt 
signaling pathway, T cell receptor signaling pathway, etc., were significantly 
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enriched (P-value < 0.05) (Figure 4-6), and many of the pathways have been 
reported to regulate muscle function and contribute to the pathogenesis of insulin 
resistance, obesity and T2D.  For example, insulin signaling pathway is one of the 
best known pathways directly regulates insulin sensitivity, and dysregulation of 
insulin signaling cascade may lead to insulin resistance and T2D (Kubota, Kubota, 
& Kadowaki, 2017; Mackenzie & Elliott, 2014).  It is noted that enriched pathways 
could share the same kinases which involve in multiple pathways; for example, 
MAPK1 and EGFR were highly cited in various signaling pathways. Among the 
identified kinases involved in insulin pathway, glycogen synthase kinase-3 beta 
(GSK3β) has been extensively reported as negative regulator of glucose 
homeostasis. GSK3β phosphorylates and inactivates glycogen synthase and thus 
attenuates glycogen synthesis. In addition, accumulating evidence suggested that 
dysregulation of mTOR signaling pathway may induce insulin resistance and T2D 
(Deblon et al., 2012; Kleinert et al., 2014; Y. Ma et al., 2015; G. I. Smith et al., 2015; 
Yin et al., 2017).  
Since protein kinases are known key regulators in the biofunctions (Figure 
4-7), multiple cellular functions were significantly enriched, such as cell activation, 
apoptosis and migration, which indicated that the active kinome in skeletal muscle 
is highly responsible for critical cell proliferation, differentiation and programmed 
cell death. In addition, oxidative stress response and cellular response to stress 
exhibited high level of significance (p-value < 0.001), which indicated that kinases 
responsible for cellular stress and survival are highly active and maintain relatively 
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high abundance in skeletal muscle insulin resistance. Furthermore, the kinases 
regulated fatty acid oxidation which is essential for acetyl-CoA and NADH 
generation (Houten & Wanders, 2010).   
Protein kinases are increasingly recognized as drug targets by which 
alternating kinase activity may correct the dysregulation of numerus substrates to 
exert therapeutic effects treating the various diseases, such as cancer and 
diabetes. Drugbank (www.drugbank.ca) is an open source database containing 
8261 drug entries that either have been approved by the FDA, or are still under 
experimental development or clinical investigational trails (Knox et al., 2011; Law 
et al., 2014; Wishart et al., 2008; Wishart et al., 2006). A comprehensive drug 
target search on the 54 functional protein kinases using Drugbank database 
suggested that 267 drug-target entries were found. Among them, 28 entries were 
FDA-approved drugs, 25 were under clinical investigation and 214 were 
experimental drugs which comprised the largest portion of the chart, which was 
expected that drug discovery and development requires substantial investments 
and research efforts (Figure 4-7). Of interest, among the 28 FDA-approved drug-
target entries (Table 4-2), metformin-AMPK1 (PRKAA1) was identified as a known 
anti-T2D agent targeting on AMPK. Metformin is the first line drug for T2D 
treatment, according to Drugbank data, metformin acts as an AMPK inducer to 
enhance AMPK activity and therefore improve insulin sensitivity. Interestingly, 
almost half (13 entries) targeted on EGFR and severed as anti-tumor agents (i.e., 
tyrosine kinase inhibitor) which mainly treat non-small cell lung cancer (NSCLC). 
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Due to the high similarities among protein kinases, one drug could target on 
multiple kinases but the therapeutic effect of the none-target kinases are remain 
unknown. For example, bosutinib, a Bcr-Abl kinase inhibitor for the treatment of 
chronic myelogenous leukemia (CML), showed multi-target effect on other kinases 
including calcium/calmodulin-dependent protein kinase type II subunit gamma 
(CAMK2G), cyclin-dependent kinase 2 (CDK2), dual specificity mitogen-activated 
protein kinase kinase 1 (MAP2K1), dual specificity mitogen-activated protein 
kinase kinase 2 (MAP2K2) and mitogen-activated protein kinase kinase kinase 2 
(MAP3K2). Despite a variety of anti-tumor agents primarily target on tyrosine 
kinases, some drugs designed as serine/threonine kinase inhibitors; for instance, 
trametinib, targeting on MAP2K1/MAP2K2, treats metastatic melanoma with BRAF 
V600E or V600K mutations. Other types of drug was also identified, such as 
lidocaine (local or regional anesthetic agent), lithium (mood stabilizer) and 
acetylsalicylic acid (pain killer).  
4.3.2 Significantly changed active kinases between lean insulin sensitive and 
obese insulin resistant participants 
The quantitative proteomics of functional kinome implied that 22 out of the 
54 identified kinases significantly changed comparing LC and OBi group (p-value 
< 0.05). Among them, 13 kinases exhibited up-regulated levels while 9 kinases 
were down-regulated in OBi subjects. It is noted that 11 kinases were only 
identified in OBi group, and 3 kinases were only identified in LC groups because 
the protein abundance of these active kinases were too low to be detected in the 
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other group. All the 22 significantly changed kinases were serine/threonine kinases 
(Table 4-3).  It is noted that this is the largest catalog of active protein kinases in 
human skeletal muscle with a significant change between LC and Obi.   
Ingenuity Pathway Analysis (IPA) of the 22 significantly changed protein 
kinases was performed to identify which cell signal transduction pathways have 
been significantly enriched, based on the criteria that minimum three kinases 
identified in each pathway and p-value must be less than 0.0001. Interestingly, the 
SAPK/JNK and IL-6 signaling were the pathway enriched with highest significant 
levels (P< 1.0E-09), and multiple other pathways were also significantly enriched: 
AMPK pathway; mTOR pathway; Type 2 diabetes signaling; ErbB signaling; ERK5 
signaling; cytokine related pathways (i.e., IL-10 signaling, JAK pathway, STAT3 
pathway, IL-17 signaling, IL-1 signaling, etc.); pathways related to oxidative stress 
and free radicals (e.g., iNOS signaling), etc.  Note that the cell signal transduction 
pathways from different databases (i.e., KEGG and IPA) may contains slightly 
different entries based on the peer-reviewed functional studies and 
knowledgebase curated by scientists. In order to visualize the abnormalities of 
function kinome involved in cell signaling and molecular functions, the quantified 
protein kinases in human skeletal was manually mapped to several significantly 
enriched pathways that covered most abnormal active protein kinases in OBi.  
Importantly, we performed IPA on the 13 protein kinases with increased 
activities and 9 kinases with decreased activities separately (Figure 4-9). For the 
up-regulated protein kinases, JNK signaling, IL-6 signaling, pathway related to 
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reactive oxygen species (ROS) in macrophages, apoptosis signaling were 
significantly enriched (P-value < 0.001 and at least 3 kinases involved); on the 
other hand, AMPK signaling, mTOR signaling, p38 MAPK signaling were 
significantly enriched in the down-regulated kinases.    
MAPK signaling pathway (downloaded from http://www.kegg.jp) (Figure 4-
10), including 15 identified protein kinases, was color-coded according to the 
differential change of functional kinome between OBi and LC. The MAP kinase 
pathway from KEGG contains three sub-signaling pathways: classic MAP kinase 
pathway (ERK1/2 pathway), JNK and p38 MAP kinase pathway (involves 
simplified NF-κB signaling) and ERK5 pathway. First, we mapped EGFR, 
serine/threonine-protein kinase B-raf (BRAF, also known as RafB), dual specificity 
mitogen-activated protein kinase kinase 1 (MAP2K1, also known as MEK1), dual 
specificity mitogen-activated protein kinase kinase 2 (MAP2K2, also known as 
MEK2), MAPK1 (also known as ERK2) and ribosomal protein S6 kinase alpha-3 
(RPS6KA3, also known as RSK2) in the ERK1/2 signaling pathway in which five 
upstream regulatory kinases of ERK2 (including ERK2 itself) didn’t exhibit 
significant changes; on the contrary, RSK2 was dramatically decreased in OBi. 
The differences of six kinases between LC and OBi involved in ERK1/2 signaling 
implied that the upstream signaling remains intact, but the substrate of ERK2 (e.g., 
RSK2) was suppressed and subsequently might inhibit downstream effectors’ 
activities (i.e., CREB) in the insulin resistance state. Second, there were 5 
identified protein kinases mainly affect JNK signaling: mitogen-activated protein 
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kinase kinase kinase kinase 4 (MAP4K4, also known as HGK), mitogen-activated 
protein kinase kinase kinase 2 (MAP3K2, also known as MEKK2), mitogen-
activated protein kinase kinase kinase 3 (MAP3K3, also known as MEKK3), 
Mitogen-activated protein kinase kinase kinase MLT (MLTK), dual specificity 
mitogen-activated protein kinase kinase 4 (MAP2K4, also known as JNKK1 or 
MEK4). Among the 5 kinases, we observed 4 significantly increased kinases 
except MLTK, which strongly suggested that JNK signaling was up-regulated in 
the skeletal muscle insulin resistance. In addition, HGK is a upstream regulator 
mediating NF-κB signaling pathway. Third, p38 MAP kinases pathway contained 4 
identified kinases which were dual specificity mitogen-activated protein kinase 
kinase 3 (MAP2K3, also known as MKK3), dual specificity mitogen-activated 
protein kinase kinase 6 (MAP2K6, also known as MKK6), mitogen-activated 
protein kinase 12 (MAPK12, also known as p38γ or SAPK3) and mitogen-activated 
protein kinase 13 (MAPK13, also known as p38𝛿 or SAPK4). Although the 
upstream kinases (MKK3 and MKK6) didn’t show significant changes, p38 MAP 
kinases were reduced significantly in OBi. Last, no identified kinase directly 
participated in ERK5 pathway, though crosstalk between MAP kinases may 
indirectly regulate ERK5 pathway (IPA database includes MKK3/6 and RSK2 in 
ERK5 pathway). 
Similarly, in the color-coded Wnt signaling pathway (downloaded from 
http://www.kegg.jp) (Figure 4-11), three kinases displayed enhanced activities: 
casein kinase II subunit alpha (CSNK2A1, also known as CK2A1), casein kinase I 
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isoform alpha (CSNK1A1, also known as CK1α), and calcium/calmodulin-
dependent protein kinase type II subunit delta (CAMK2D); three kinases did not 
show significant change: GSK3β, casein kinase II subunit alpha’ (CSNK2A2, also 
known as CK2A2), calcium/calmodulin-dependent protein kinase type II subunit 
gamma (CAMK2G); one kinase was down-regulated: calcium/calmodulin-
dependent protein kinase type II subunit beta (CAMK2B). Note since CK2A1 and 
CK2A2 are isoforms of CK2, so half of the CK2 block was colored in red (increased) 
and half in yellow (no change). Similarly, CAMK2D, CAMK2G and CAMK2B are 
different subunits of CaMKII, which was colored differently according to the 
differential changes of its subunits in LC and OBi.   
We color-coded mTOR signaling pathway (downloaded from 
http://www.kegg.jp) (Figure 4-12) using the same approach described above to 
map functional kinome in human skeletal muscle. Multiple protein kinases in the 
mTOR signaling have been significantly suppressed, such as serine/threonine-
protein kinase STK11 (STK11, also known as LKB1), 5'-AMP-activated protein 
kinase catalytic subunit alpha-1 (PRKAA1, also known as AMPK1), 5'-AMP-
activated protein kinase catalytic subunit alpha-2 (PRKAA2, also known as AMPK2) 
and RSK2; while Raf, MEK, ERK1/2, and GSK3β did not exhibit significant 
changes between LC and OBi.  
Of interest, significantly changed protein kinases of AMPK signaling 
pathway (adapted from IPA) was also highlighted. Totally, five kinases, AMPK1, 
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AMPK2, p38γ, p38𝛿 and LKB1, were involved and all of them were significantly 
decreased.  
Protein kinases are highly regulated by other kinases or 
autophosphorylation, a significant enriched functional kinome network of the 
insulin resistance responsible active kinases was constructed by IPA (Figure 4-14). 
The network is related to post translational modification and cell survival, 
differentiation and proliferation with score 43 (highest scored network, maximum 
molecules was set at 70), which contains 21 significantly changed kinases (11 up-
regulated kinases highlighted in red and 10 down-regulated kinases highlighted in 
green) and 13 other known proteins/protein complexes in the IPA database but 
were not identified in current study.  
4.4 Discussion  
Protein kinases, enzymes catalyzing phosphorylation, play critical roles in 
numerous biological processes and molecular functions, such as insulin signaling, 
glucose uptake, etc. On the other hand, dysregulation of protein kinases might 
results in variety of unhealthy states and diseases (e.g., obesity, insulin resistance, 
and T2D). Skeletal muscle insulin resistance has been well defined as a primary 
defect of T2D. Currently, dysregulation of protein kinases have been reported to 
lead to skeletal muscle insulin resistance; however, most of the studies only 
focused on the protein abundance or phosphorylation of few protein kinases in cell 
or animal models (Sakiyama, Usuki, Sakai, & Sakane, 2014; B. K. Smith et al., 
2013; Tunduguru et al., 2014). No high-throughput profiling of active protein 
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kinases in skeletal muscle biopsies of obese insulin resistant participants has been 
reported to date. The global functional kinome in human skeletal muscle insulin 
resistance remains unknown. Therefore, we developed a platform combining 
activity-based kinase enrichment technique and quantitative proteomics to profile 
active protein kinases in human skeletal muscle in lean healthy subjects and obese 
participants with insulin resistance, and sought to unveil novel functional kinome 
responsible for insulin resistance and obesity. Compared to previous studies, the 
main innovations were 1) profiling dozens of active kinases other than protein 
abundance or phosphorylation sites of few kinases; 2) providing a direct and 
relative global assessment of kinase activities in vivo other than traditional 
radioactive kinase activity assay which requires binding substrates; 3) Improved 
coverage and accuracy of quantitative proteomics using “Universal” SILAC; 4) 
providing a comprehensive view of significantly enriched cell signaling pathways 
by multiple bioinformatics databases. In contrast, the challenges of current study 
were: 1) highly complex biological samples (i.e., skeletal muscle biopsy) with 
multiple high abundant contractile proteins (i.e., myosin, nebulin, titin, etc.) may 
interfere relative low abundant kinome profiling; 2) data dependent acquisition 
mode of “shotgun” proteomics might miss extremely low abundant proteins 
compared to target proteomics, which is more sensitive than shotgun proteomics 
but with relative low throughput. This approach is applicable for functional kinome 
enrichment in various biological samples in different species.  
4.4.1 Inflammatory response pathways in skeletal muscle insulin resistance 
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Increasing evidence suggests accumulation of immune cells (i.e., T 
lymphocytes, macrophages, etc.) in skeletal muscle cells (myotubes) in obesity 
with insulin resistance and T2D (Fink et al., 2014; Fink et al., 2013; Khan et al., 
2015; Patsouris et al., 2014; Varma et al., 2009). It is well established that 
proinflammatory cytokines (e.g., TNFα, IL-1, IL-6) lead to inflammation via 
inflammatory response pathways, such as JNK signaling, NF-κB signaling, IL-6 
signaling, etc (Hou et al., 2008; Sanchez et al., 2012; Spiga et al., 2017; Zhong et 
al., 2009). In present study, the pathway analysis (Figure4-8) of the 22 protein 
kinases significantly changed in OBi compared to LC suggested that multiple 
inflammatory response pathways (e.g., JNK signaling, IL-6 signaling, IL-10 
signaling) have been significantly enriched.  
JNK has been demonstrated as a critical mediator in insulin resistance and 
obesity (Chiang et al., 2009; Hirosumi et al., 2002), Senn JJ (Senn, 2006) reported 
increased JNK activity in insulin resistance myotubes, and Vijayvargia R and 
associates (Vijayvargia, Mann, Weiss, Pownall, & Ruan, 2010) performed JNK 
knockdown which enhanced the glycogen storage in skeletal muscle cells from 
mice. In this study, we found 4 significantly increased active protein kinases 
(JNKK1, MEKK2, MEKK3 and HGK) in JNK signaling pathway (Figure 4-10) in OBi. 
JNKK1 directly phosphorylates and activates JNK, and JNNK1 is regulated by 
MEKK2 and MEKK3 kinase activities. Also, HGK or MAP4K4 has been reported 
to play a central role in JNK and p38 MAPK signaling, serving as an upstream 
regulator (Yao et al., 1999). Serine/threonine-protein kinase 38 (STK38) was 
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significantly increased in OBi (not on the KEGG mapped JNK pathway). Although 
STK38 was reported as a negative regulator of JNK pathway by inhibiting 
autophosphorylation of MEKK1/2 (Enomoto et al., 2008), other regulatory 
compensation may also affect MEKK1/2 activity. Despite we did not observe active 
JNK directly (might be low abundant), four upstream kinases (especially JNNK1) 
of JNK with increased activities strongly suggested that JNK signaling was 
activated in human skeletal muscle insulin resistance. It is noted that 
hyperglycemia may induce JNK activity (Hein, Xu, Xu, & Kuo, 2016), however, JNK 
activity could remain unchanged in the current study because the participants in 
our study have normal glucose homeostasis (normal fasting plasma glucose, 
HbA1c, and 2-h OGTT) even though their skeletal muscle is insulin resistant.  
Although, overwhelming evidence implies up-regulated JNK signaling may reduce 
insulin sensitivity or impair insulin signaling pathway via increased IRS1 S307 
phosphorylation (Henstridge et al., 2012; Sabio et al., 2010), Zbinden FH and 
associates (Zbinden-Foncea, Raymackers, Deldicque, Renard, & Francaux, 2012) 
reported that endurance exercise (likely increases insulin sensitivity) increased 
JNK and p38 MAPK activity in skeletal muscle from mice with T2D, which seems 
contrast from our finding and findings from other groups. However, physiological 
and pathological of mice with T2D might be different from those of human, and 
majority of the studies are still consistent with our results.  
4.4.2 p38 MAPK signaling 
84 
 
 
 
p38 MAPK signaling may also contribute to obesity linked insulin resistance. 
Emerging evidence suggests that inhibition of p38 may results in impaired insulin 
dependent glucose uptake in skeletal muscle and adipocytes (Sweeney et al., 
1999). Furthermore, Somwar et al., (Somwar et al., 2001) observed significantly 
decreased GLUT4 translocation by p38 inhibitor in L6 rat skeletal muscle cells, 
which suggested that p38 inhibitors impaired insulin stimulated glucose uptake 
through a GLUT4 translocation manner. On the other hand, a study showed p38 
inducer activated glucose uptake via AMPK-GLUT4 signaling and enhanced 
insulin sensitivity (P. C. Geiger, Wright, Han, & Holloszy, 2005). However, based 
on our literature search, no study has been conducted on active p38 MAPK in 
insulin resistant skeletal muscle from obese participants. In this study, we identified 
two p38 activation kinases, MKK3 and MKK6, which remained no change; 
surprisingly, two out of four p38 MAPKs (p38γ and p38𝛿) were identified in our 
dataset, and their kinase activity was significantly reduced, which supports the 
decreased p38 activity may reduce the insulin-stimulated glucose uptake and 
cause insulin resistance via impaired AMPK (which was found ~ 9.0 fold reduced 
in our study) mediated glucose transport. Although the molecular mechanism of 
down-regulated p38 in peripheral insulin resistance is incompletely understood, we 
provided an evidence of attenuation of p38 MAPK signaling in human skeletal 
muscle insulin resistance. Not surprisingly, controversial results still exist, for 
example, it is reported that low dose oxidative stress transiently induced p38 
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MAPK activity and resulted in insulin resistance in isolated rat skeletal muscle 
(Diamond-Stanic et al., 2011). 
4.4.3 Wnt pathway 
Of interest, we identified 7 protein kinases in Wnt pathway, specifically, 4 in 
Wnt canonical pathway and 3 in Wnt/Ca2+ pathway (Figure 4-11). Growing data 
shows that Wnt signaling was important for development and carcinogenesis, and 
inhibition of Wnt signaling could suppress various tumor growth (Demagny, Araki, 
& De Robertis, 2014; M. Kahn, 2015; H. Liu et al., 2014; Morrow et al., 2016; Reno 
et al., 2016; Uehara, Kage-Nakadai, Yoshina, Imae, & Mitani, 2015; W. Zhang et 
al., 2016). In addition, Wnt signaling is also activated by anti-inflammatory 
cytokines (such TGFβ) (Castellone & Laukkanen, 2017; Jardim, Poco, & Campos, 
2017). In the canonical pathway, CK1, axin, adenomatosis polyposis coli (APC) 
and GSK3β forms destruction complex which degrades β-catenin via ubiquitination. 
In the absence of Wnt signaling (Wnt-off), CK1 and GSK3β constantly 
phosphorylate β-catenin which subsequently undergoes protein degradation; on 
the other hand, the destruction complex become inactive upon Wnt ligand binding 
(Wnt-on), and β-catenin is activated and transferred to nucleus (Minde, Anvarian, 
Rudiger, & Maurice, 2011; Minde, Radli, Forneris, Maurice, & Rudiger, 2013). 
Previously reports indicated that beta-catenin gene expression was lower in 
adipose tissue and skeletal muscle of subjects with low insulin sensitivity 
compared to those with high insulin sensitivity subjects (Karczewska-Kupczewska, 
Stefanowicz, Matulewicz, Nikolajuk, & Straczkowski, 2016). In present study, CK1, 
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a key inhibitor of β-catenin, was significantly increased in OBi, so β-catenin might 
be suppressed in OBi. Compelling evidence shows β-catenin plays critical role in 
glucose homeostasis and insulin secretion. Early works (Dabernat et al., 2009) 
indicated that deletion of β-catenin in mice islet cells induced severe dysregulation 
of glucose homeostasis. Later on, Elghazi et al., (Elghazi et al., 2012) observed 
that β-catenin knockout in pancreatic progenitors led to impaired glucose tolerance. 
Recently, Sorrenson, B. and colleagues reported that reduced β-catenin gene 
expression in β-cell could increase glucose-stimulated insulin secretion. 
Furthermore, the molecular mechanism of CK1/β-catenin induced abnormal 
insulin-dependent glucose disposal may be involved in muscle contraction and 
interaction with actin cytoskeleton (Galli et al., 2012; Nagashima et al., 1997). 
Therefore, we first reported that decreased CK1/β-catenin complex activity might 
be responsible for impaired insulin stimulated glucose uptake and 
hyperinsulinemia in insulin resistant skeletal muscle of obese participants. Noted 
that some researchers observed up-regulated Wnt signaling in diabetes (Garcia-
Jimenez, Garcia-Martinez, Chocarro-Calvo, & De la Vieja, 2014), which provided 
other possible molecular mechanism of CK1/β-catenin complex regulating insulin 
resistance and diabetes related pathways.  
There were three CaMKII subunits involved in Wnt/Ca2+ pathway; however, 
differential changes of them in OBi (one increase, one decrease and one no 
change) were observed. CaMKII plays important role in skeletal muscle during 
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exercise, and exercise induced more than 5 fold changes of phosphorylation at 
Thr287 of CaMKII in skeletal muscle (Rose, Kiens, & Richter, 2006).  
4.4.4 mTOR signaling pathway  
As described in the introduction part, mTOR is an atypical kinase which 
lacks of typical kinase catalytic core; therefore, current platform was not capable 
to enrich active mTOR. As predicted, we did not identify mTOR itself but did identify 
other upstream regulatory kinases which could affect mTOR activity (Figure 4-12). 
Among the protein kinases mapped to mTOR pathway, some of them mainly 
involved in AMPK signaling pathway (Figure 4-13), and rest of them primarily 
participated in ERK1/2 pathway.  
4.4.4.1 AMPK pathway   
AMPK is a protein kinase regulated by AMP/ATP ratio in cellular 
microenvironment, and it could boost ATP generation and reduce utilization of ATP 
(Carling, Zammit, & Hardie, 1987).  Overwhelming evidence indicates AMPK 
activity was overall attenuated in insulin resistance, obesity and T2D (Coughlan, 
Valentine, Ruderman, & Saha, 2013; Dzamko et al., 2010; Gauthier et al., 2011; 
Yamada, Lee, Pessin, & Bastie, 2010). However, whether AMPK exhibiting 
reduced activity in skeletal muscle insulin resistance mostly yielded the 
controversial results. Bandyopadhyay et al., (Bandyopadhyay, Yu, Ofrecio, & 
Olefsky, 2006) suggested decreased AMPK level in skeletal muscle from obesity 
and T2D; while Liong, S. and Lappas, M. colleagues reported activated AMPK in 
pregnant women with gestational diabetes (Liong & Lappas, 2015). Similarly, 
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exercise stimulated AMPK activity in skeletal is still filled up with mixed conclusions. 
For example, McGee et al., (McGee et al., 2003) stated that acute exercise 
significantly increased AMPK activity in insulin resistant skeletal muscle, but 
Sriwijitkamol and associates reported attenuated AMPK activity after acute 
exercise in skeletal muscle of obese participants with insulin resistance and T2D 
(Sriwijitkamol et al., 2007). On one hand, numerous controversial studies of AMPK 
activity in skeletal muscle insulin resistance exist; on the other hand, no study 
directly assessing the active AMPK in skeletal muscle of obesity with insulin 
resistance and hyperinsulinemia. Increasing data shows that AMPK is also 
regulated by inflammation, ER stress and oxidative stress, which are typically 
increased in obesity with insulin resistance and led to increased AMPK activity (C. 
C. Chen et al., 2014; Gautam et al., 2016; W. Li et al., 2015; Manna & Jain, 2013). 
In contrast, decreased AMPK activity reduces glucose uptake in skeletal muscle 
insulin resistance and T2D. In Figure 4-13, we quantified active LKB1 and 
AMPK1/2 which were decreased by 11.9 and 9.5 in OBi, representatively. LKB1 is 
a well-defined AMPK positive regulator that directly phosphorylates AMPK (Forcet 
& Billaud, 2007; Hardie, 2005; Rider, 2006; Sriwijitkamol et al., 2006) whereas the 
two p38 MAPKs (decreased in OBi) indirectly mediate AMPK activity via MKK3 (no 
change). Our results provided evidence that AMPK signaling pathway was 
significantly attenuated in OBi compared to LC.  
4.4.4.2 ERK1/2 signaling 
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Another pathway mediated mTOR signaling is ERK1/2 pathway which is a 
central axis for numerous molecular functions (e.g., cell proliferation and 
differentiation) and cell signal transduction, such as insulin signaling. Multiple 
studies of the ERK1/2 activity in skeletal muscle of obesity and T2D demonstrated 
mix results. First, Krook et al., (Krook et al., 2000) reported no significant difference 
of ERK1/2 activity compared lean subjects and T2D, and Cusi et al., (Cusi et al., 
2000) observed similar results in human skeletal muscle biopsies; in contrast, 
other researchers observed increased ERK1/2 phosphorylation in basal state of 
obesity and T2D (Bandyopadhyay, Yu, Ofrecio, & Olefsky, 2005). In present study, 
RafB, MEK1, MEK2, and ERK2 did not show significant change; however, RSK2 
was attenuated in OBi.  
4.4.4.3 AMPK and ERK1/2 signaling crosstalk with mTOR signaling 
For the active kinase in the AMPK and ERK1/2 pathway identified in the 
study, only LKB1, AMPK1/2 and RSK2 were significantly changed (decreased) in 
OBi compared to LC. Emerging evidence suggests that LKB1/AMPK complex is a 
negative regulator of mTOR (Dong et al., 2013; D. Han, Li, Zhu, Liu, & Li, 2013; 
Shaw et al., 2004); however, Han et al., observed unchanged mTOR activity with 
impaired LKB1/AMPK in rat adipose tissue (J. Han et al., 2016). One of ERK1/2 
downstream kinases, RSK2, directly phosphorylates ribosomal protein S6 (RPS6) 
and Eukaryotic translation initiation factor 4B (EIF4B), and regulates cell 
proliferation and differentiation. RSK2 inactivates GSK3β which is a negative 
mediator for glycogen synthesis by which RSK2 is a positive regulator for insulin 
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sensitivity (Sutherland, Leighton, & Cohen, 1993). MAPK stimulates the mTORC1 
activity via RSK1/2 independently of PI3K/AKT pathway. Taken with the findings 
in this study, mTOR signaling might remain unchanged because, based on the 
literatures, LKB1/AMPK may up-regulate mTOR while RSK2 (positive regulator) 
may down-regulate mTOR activity; however, numerous factors could also alter 
mTOR signaling. Therefore, further validation of mTOR and other key protein 
kinases are required.   
4.5 Summary 
In Specific Aim 1, from 8 lean healthy participants and 8 obese participants 
with insulin resistance using activity-based ATP probes and quantitative 
proteomics analysis, we identified 54 active protein kinases in human skeletal 
muscle, which is the largest catalog of experimental determined active kinases to 
date. Twenty-two out of the 54 active kinases displayed a significant change in 
insulin resistant obese subjects, including the protein kinases regulate JNK 
signaling, p38 MAPK signaling, Wnt signaling, AMPK signaling, ERK1/2 signaling 
and mTOR signaling. We generated a relative global picture of functional kinome 
in skeletal muscle insulin resistance, providing novel insights into abnormal 
functional kinome and molecular mechanism of skeletal muscle insulin resistance. 
These results may facilitate identifying new targets for treating metabolic diseases.  
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Figure 4-4. Flowchart of active protein kinase identification and 
quantification. 
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Figure 4-5. Significantly enriched canonical pathways for the 54 identified 
protein kinases. Data label on the bar represents the number of protein kinases 
participated in that pathway.  
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Figure 4-6. Significantly enriched biological functions for the 54 identified 
protein kinases. Data label on the bar represents the number of protein kinases 
participated in that biofunction.  
 
 
 
Figure 4-7. Drugbank database search on the 54 identified protein kinases. 
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Figure 4-8. Ingenuity pathway analysis on the 22 significantly changed 
kinases. Data label on the bar represents the number of protein kinases 
participated in that pathway.  
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Figure 4-9. Ingenuity pathway analysis on the up-regulated kinases versus 
the down-regulated kinases. Data label on the bar represents the number of 
protein kinases participated in that pathway.  
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Figure 4-10. Color-coded MAPK signaling pathway of functional kinome 
according to their differences in LC and OBi. Figure of MAPK signaling pathway 
was adapted from KEGG. 
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Figure 4-11. Color-coded Wnt signaling pathway of functional kinome 
according to their differences in LC and OBi. Figure of Wnt signaling pathway 
was adapted from KEGG. 
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Figure 4-12. Color-coded mTOR signaling pathway of functional kinome 
according to their differences in LC and OBi. Figure of mTOR signaling 
pathway was adapted from KEGG. 
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Figure 4-13. Color-coded AMPK signaling pathway of functional kinome 
according to their differences in LC and OBi. Figure of AMPK signaling pathway 
was adapted from IPA. 
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Figure 4-14. A significantly enriched functional kinome network of the 
differential changed protein kinases in human skeletal muscle insulin 
resistance. Color-coded network was output from IPA. Solid line is indicating 
direct interactions and dashed line is indicating indirect interactions. 
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Table 4-1.  Identified 71 active protein kinase lysine sites in skeletal muscle 
insulin resistance. 
Gene 
Name 
Protein Name Modified sequence 
Desthiobi
otin K 
positions 
within 
proteins 
Binding K 
type 
BRAF 
Serine/threonine-protein 
kinase B-raf 
DLK(de)SNNIFLHEDL
TVK 578 
Catalytic 
Domain 
CAMK2B 
Calcium/calmodulin-
dependent protein kinase 
type II subunit beta 
LCTGHEYAAK(de)IIN
TK 43 
ATP binding 
Site 
CAMK2D 
Calcium/calmodulin-
dependent protein kinase 
type II subunit delta 
IPTGQEYAAK(de)IIN
TK 43 
ATP binding 
Site 
CAMK2G 
Calcium/calmodulin-
dependent protein kinase 
type II subunit gamma 
TSTQEYAAK(de)IINT
K 43 
ATP binding 
Site 
CDK16 Cyclin-dependent kinase 16 DLK(de)PQNLLINER 288 
Catalytic 
Domain 
CDK16 Cyclin-dependent kinase 16 LTDNLVALK(de)EIR 194 
ATP binding 
Site 
CDK2 Cyclin-dependent kinase 2 
DLK(de)PQNLLINTEG
AIK 129 
Catalytic 
Domain 
CDK5 Cyclin-dependent kinase 5 DLK(de)PQNLLINR 128 
Catalytic 
Domain 
CDK5 Cyclin-dependent kinase 5 NRETHEIVALK(de)R 33 
ATP binding 
Site 
CSNK1A1 Casein kinase I isoform alpha 
DIK(de)PDNFLMGIG
R 138 
Catalytic 
Domain 
CSNK2A1 Casein kinase II subunit alpha 
DVK(de)PHNVMIDH
EHR 158 
Catalytic 
Domain 
CSNK2A2 
Casein kinase II subunit 
alpha' 
DVK(de)PHNVM(ox)I
DHQQK 159 
Catalytic 
Domain 
EGFR 
Epidermal growth factor 
receptor IPVAIK(de)ELR 745 
ATP binding 
Site 
EIF2AK2 
Interferon-induced, double-
stranded RNA-activated 
protein kinase DLK(de)PSNIFLVDTK 416 
Catalytic 
Domain 
GSK3A 
Glycogen synthase kinase-3 
alpha 
DIK(de)PQNLLVDPD
TAVLK 246 
Catalytic 
Domain 
GSK3B 
Glycogen synthase kinase-3 
beta 
DIK(de)PQNLLLDPDT
AVLK 183 
Catalytic 
Domain 
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MAP2K1 
Dual specificity mitogen-
activated protein kinase 
kinase 1 DVK(de)PSNILVNSR 192 
Catalytic 
Domain 
MAP2K1 
Dual specificity mitogen-
activated protein kinase 
kinase 1 K(de)LIHLEIKPAIR 97 
ATP binding 
Site 
MAP2K2 
Dual specificity mitogen-
activated protein kinase 
kinase 2 DVK(de)PSNILVNSR 196 
Catalytic 
Domain 
MAP2K2 
Dual specificity mitogen-
activated protein kinase 
kinase 2 K(de)LIHLEIKPAIR 101 
ATP binding 
Site 
MAP2K3 
Dual specificity mitogen-
activated protein kinase 
kinase 3 DVK(de)PSNVLINK 192 
Catalytic 
Domain 
MAP2K3 
Dual specificity mitogen-
activated protein kinase 
kinase 3 HAQSGTIMAVK(de)R 93 
ATP binding 
Site 
MAP2K4 
Dual specificity mitogen-
activated protein kinase 
kinase 4 DIK(de)PSNILLDR 231 
Catalytic 
Domain 
MAP2K4 
Dual specificity mitogen-
activated protein kinase 
kinase 4 
PSGQIM(ox)AVK(de)
R 131 
ATP binding 
Site 
MAP2K6 
Dual specificity mitogen-
activated protein kinase 
kinase 6 
LSVIHRDVK(de)PSNV
LINAL 181 
Catalytic 
Domain 
MAP2K6 
Dual specificity mitogen-
activated protein kinase 
kinase 6 
M(ox)RHVPSGQIM(o
x)AVK(de)R 82 
ATP binding 
Site 
MAP3K2 
Mitogen-activated protein 
kinase kinase kinase 2 DIK(de)GANILR 482 
Catalytic 
Domain 
MAP3K3 
Mitogen-activated protein 
kinase kinase kinase 3 DIK(de)GANILR 491 
Catalytic 
Domain 
MAP4K4 
Mitogen-activated protein 
kinase kinase kinase kinase 4 
DIK(de)GQNVLLTEN
AEVK 155 
Catalytic 
Domain 
MAP4K5 
Mitogen-activated protein 
kinase kinase kinase kinase 5 
DIK(de)GANILLTDHG
DVK 142 
Catalytic 
Domain 
MAP4K5 
Mitogen-activated protein 
kinase kinase kinase kinase 5 
NVHTGELAAVK(de)II
K 49 
ATP binding 
Site 
MAPK1 
Mitogen-activated protein 
kinase 1 
DLK(de)PSNLLLNTTC
DLK 151 
Catalytic 
Domain 
MAPK12 
Mitogen-activated protein 
kinase 12 
DLK(de)PGNLAVNED
CELK 155 
Catalytic 
Domain 
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MAPK13 
Mitogen-activated protein 
kinase 13 
DLK(de)PGNLAVNED
CELK 152 
Catalytic 
Domain 
MARK2 
Serine/threonine-protein 
kinase MARK2 
DLK(de)AENLLLDAD
M(ox)NIK 177 
Catalytic 
Domain 
MARK3 
MAP/microtubule affinity-
regulating kinase 3 
DLK(de)AENLLLDAD
M(ox)NIK 180 
Catalytic 
Domain 
MARK3 
MAP/microtubule affinity-
regulating kinase 3 EVAIK(de)IIDK 85 
ATP binding 
Site 
MARK4 
MAP/microtubule affinity-
regulating kinase 4 EVAIK(de)IIDK 88 
ATP binding 
Site 
MAST1 
Microtubule-associated 
serine/threonine-protein 
kinase 1 
DLK(de)PDNLLITSM(
ox)GHIK 499 
Catalytic 
Domain 
MAST2 
Microtubule-associated 
serine/threonine-protein 
kinase 2 
DLK(de)PDNLLITSM(
ox)GHIK 637 
Catalytic 
Domain 
MAST3 
Microtubule-associated 
serine/threonine-protein 
kinase 3 
DLK(de)PDNLLITSLG
HIK 492 
Catalytic 
Domain 
MINK1 Misshapen-like kinase 1 
DIK(de)GQNVLLTEN
AEVK 155 
Catalytic 
Domain 
MLTK 
Mitogen-activated protein 
kinase kinase kinase MLT WISQDKEVAVKK(de) 46 
ATP binding 
Site 
MST4 
Serine/threonine-protein 
kinase MST4 
DIK(de)AANVLLSEQ
GDVK 146 
Catalytic 
Domain 
NEK6 
Serine/threonine-protein 
kinase Nek6 
DIK(de)PANVFITATG
VVK 174 
Catalytic 
Domain 
NEK7 
Serine/threonine-protein 
kinase Nek7 
DIK(de)PANVFITATG
VVK 163 
Catalytic 
Domain 
NEK7 
Serine/threonine-protein 
kinase Nek7 
AACLLDGVPVALK(de
)K 63 
ATP binding 
Site 
NEK9 
Serine/threonine-protein 
kinase Nek9 DIK(de)TLNIFLTK 178 
Catalytic 
Domain 
NEK9 
Serine/threonine-protein 
kinase Nek9 LGDYGLAK(de)K 81 
ATP binding 
Site 
OXSR1 
Serine/threonine-protein 
kinase OSR1 
DVK(de)AGNILLGED
GSVQ 148 
Catalytic 
Domain 
PRKAA1 
5'-AMP-activated protein 
kinase catalytic subunit 
alpha-1 
DLK(de)PENVLLDAH
MNAK 152 
Catalytic 
Domain 
PRKAA1 
5'-AMP-activated protein 
kinase catalytic subunit 
alpha-1 VAVK(de)ILNR 56 
ATP binding 
Site 
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PRKAA2 
5'-AMP-activated protein 
kinase catalytic subunit 
alpha-2 
DLK(de)PENVLLDAH
MNAK 141 
Catalytic 
Domain 
PRKAA2 
5'-AMP-activated protein 
kinase catalytic subunit 
alpha-2 VAVK(de)ILNR 45 
ATP binding 
Site 
RPS6KA1 
Ribosomal protein S6 kinase 
alpha-1 
DLK(de)PENILLDEEG
HIK 189 
Catalytic 
Domain 
RPS6KA2 
Ribosomal protein S6 kinase 
alpha-2 
DLK(de)PENILLDEEG
HIK 186 
Catalytic 
Domain 
RPS6KA3 
Ribosomal protein S6 kinase 
alpha-3 
DLK(de)PSNILYVDES
GNPESIR 541 
Catalytic 
Domain 
RPS6KA3 
Ribosomal protein S6 kinase 
alpha-3 
DLK(de)PENILLDEEG
HIK 195 
Catalytic 
Domain 
SLK 
STE20-like serine/threonine-
protein kinase 
DLK(de)AGNILFTLDG
DIK 157 
Catalytic 
Domain 
SLK 
STE20-like serine/threonine-
protein kinase 
ETSVLAAAK(de)VIDT
K 63 
ATP binding 
Site 
STK10 
Serine/threonine-protein 
kinase 10 
DLK(de)AGNVLMTLE
GDIR 159 
Catalytic 
Domain 
STK11 
Serine/threonine-protein 
kinase STK11 
DIK(de)PGNLLLTTGG
TLK 178 
Catalytic 
Domain 
STK24 
Serine/threonine-protein 
kinase 24 
DIK(de)AANVLLSEH
GEVK 158 
Catalytic 
Domain 
STK25 
Serine/threonine-protein 
kinase 25 
DIK(de)AANVLLSEQ
GDVK 142 
Catalytic 
Domain 
STK38 
Serine/threonine-protein 
kinase 38 DIK(de)PDNLLLDSK 214 
Catalytic 
Domain 
STK38 
Serine/threonine-protein 
kinase 38 DTGHVYAMK(de)ILR 118 
ATP binding 
Site 
STK38L 
Serine/threonine-protein 
kinase 38-like DTGHIYAMK(de)ILR 119 
ATP binding 
Site 
TNIK 
TRAF2 and NCK-interacting 
protein kinase 
DIK(de)GQNVLLTEN
AEVK 155 
Catalytic 
Domain 
TP53RK TP53-regulating kinase 
FLSGLELVK(de)QGAE
AR 40 
ATP binding 
Site 
ULK3 
Serine/threonine-protein 
kinase ULK3 
NISHLDLK(de)PQNIL
LS 139 
Catalytic 
Domain 
ULK3 
Serine/threonine-protein 
kinase ULK3 EVVAIK(de)CVAK 44 
ATP binding 
Site 
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Table 4-2.  Twenty-eight FDA-approved drug-target entries on the functional 
kinome in human skeletal muscle insulin resistance. 
Gene 
Name 
Protein Name 
Approved drug 
name 
Drug 
Bank ID 
Pharmacology 
PRKAA1 
5'-AMP-activated 
protein kinase 
catalytic subunit 
alpha-1 
Acetylsalicylic 
acid 
DB00945 
Treatment of mild to 
moderate pain 
PRKAA1 
5'-AMP-activated 
protein kinase 
catalytic subunit 
alpha-1 
Adenosine 
monophosphate 
DB00131 Nutritional supplementation 
PRKAA1 
5'-AMP-activated 
protein kinase 
catalytic subunit 
alpha-1 
Metformin DB00914 
 Treatment of type II 
diabetes mellitus, kinase 
inducer 
CAMK2G 
Calcium/calmodulin-
dependent protein 
kinase type II 
subunit gamma 
Bosutinib DB06616 
 Treatment of chronic 
myelogenous leukemia 
(CML) 
CDK2 
Cyclin-dependent 
kinase 2 
Bosutinib DB06616 
 Treatment of chronic 
myelogenous leukemia 
(CML)  
MAP2K1 
Dual specificity 
mitogen-activated 
protein kinase 
kinase 1 
Bosutinib DB06616 
 Treatment of chronic 
myelogenous leukemia 
(CML) 
MAP2K1 
Dual specificity 
mitogen-activated 
protein kinase 
kinase 1 
Cobimetinib DB05239 
 Treatment of metastatic 
melanoma, MAPK inhibitor  
MAP2K1 
Dual specificity 
mitogen-activated 
protein kinase 
kinase 1 
Trametinib DB08911 
 Treatment of metastatic 
melanoma with BRAF V600E 
or V600K mutations 
MAP2K2 
Dual specificity 
mitogen-activated 
protein kinase 
kinase 2 
Bosutinib DB06616 
 Treatment of chronic 
myelogenous leukemia 
(CML) 
MAP2K2 
Dual specificity 
mitogen-activated 
protein kinase 
kinase 2 
Trametinib DB08911 
 Treatment of metastatic 
melanoma with BRAF V600E 
or V600K mutations 
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EGFR 
Epidermal growth 
factor receptor 
Afatinib DB08916 
 Treatment of metastatic 
non-small cell lung cancer, 
Tyrosine kinase inhibitor 
EGFR 
Epidermal growth 
factor receptor 
Cetuximab DB00002 
 Treatment of metastatic 
colorectal carcinoma, 
Tyrosine kinase inhibitor 
EGFR 
Epidermal growth 
factor receptor 
Erlotinib DB00530 
 Treatment of metastatic 
non-small cell lung cancer, 
Tyrosine kinase inhibitor 
EGFR 
Epidermal growth 
factor receptor 
Gefitinib DB00317 
 Treatment of metastatic 
non-small cell lung cancer, 
Tyrosine kinase inhibitor 
EGFR 
Epidermal growth 
factor receptor 
Icotinib DB11737 
 Treatment of metastatic 
non-small cell lung cancer, 
Tyrosine kinase inhibitor 
EGFR 
Epidermal growth 
factor receptor 
Lapatinib DB01259 
 Treatment of metastatic 
breast cancer, Tyrosine 
kinase inhibitor 
EGFR 
Epidermal growth 
factor receptor 
Lidocaine DB00281 
Treatment of Local or 
regional anesthesia  
EGFR 
Epidermal growth 
factor receptor 
Necitumumab DB09559 
 Treatment of non-small cell 
lung cancer, Tyrosine kinase 
inhibitor 
EGFR 
Epidermal growth 
factor receptor 
Olmutinib DB13164 
Treatment of metastatic 
T790M mutation positive 
non-small cell lung cancer 
EGFR 
Epidermal growth 
factor receptor 
Osimertinib DB09330 
Treatment of metastatic 
T790M mutation positive 
non-small cell lung cancer 
EGFR 
Epidermal growth 
factor receptor 
Panitumumab DB01269 
Treatment of EGFR-
expressing, metastatic 
colorectal carcinoma 
EGFR 
Epidermal growth 
factor receptor 
Trastuzumab DB00072 
Treatment of HER2-positive 
breast cancer 
EGFR 
Epidermal growth 
factor receptor 
Vandetanib DB05294 
Treatment of metastatic 
medullary thyroid cancer  
GSK3B 
Glycogen synthase 
kinase-3 beta 
Lithium DB01356 
Mood stabilizer, kinase 
inhibitor 
MAPK1 
Mitogen-activated 
protein kinase 1 
Arsenic trioxide DB01169 
 Treatment of acute 
promyelocytic leukemia 
(APL), 
MAPK1 
Mitogen-activated 
protein kinase 1 
Isoprenaline DB01064 
Treatment of mild or 
transient episodes of heart 
block 
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MAP3K2 
Mitogen-activated 
protein kinase 
kinase kinase 2 
Bosutinib DB06616 
 Treatment of chronic 
myelogenous leukemia 
(CML) 
RPS6KA3 
Ribosomal protein 
S6 kinase alpha-3 
Acetylsalicylic 
acid 
DB00945 
Treatment of mild to 
moderate pain 
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Table 4-3.  Twenty-two significantly changed protein kinases in obesity with 
insulin resistance. 
Gene 
Name 
Protein Name 
Protein 
ID 
Desthiob
iotin K 
positions 
within 
proteins 
Binding K 
Type 
Fold Change 
OBi/LC 
Mean ± 
SEM 
MAPK12  
Mitogen-activated protein 
kinase 12 P53778 152 
catalytic 
domain 0 
MAPK13 
Mitogen-activated protein 
kinase 13 P53778 152 
catalytic 
domain 0 
RPS6KA3  
Ribosomal protein S6 
kinase alpha-3 P51812 541 
Catalytic 
domain 0 
CAMK2B 
Calcium/calmodulin-
dependent protein kinase 
type II subunit beta Q13554 43 
ATP binding 
site 0.06 ± 0.01 
STK11 
Serine/threonine-protein 
kinase STK11 Q15831 178 
catalytic 
domain 0.08 ± 0.02 
PRKAA2 
5'-AMP-activated protein 
kinase catalytic subunit 
alpha-2 P54646 45 
ATP binding 
site 0.11 ± 0.03 
PRKAA1 
5'-AMP-activated protein 
kinase catalytic subunit 
alpha-1 Q13131 56 
ATP binding 
site 0.11± 0.03 
MARK3 
MAP/microtubule affinity-
regulating kinase 3 J3KNR0 85 
ATP binding 
site 0.22 ± 0.07 
GSK3A 
Glycogen synthase kinase-3 
alpha P49840 246 
catalytic 
domain 0.30 ± 0.04 
CAMK2D 
Calcium/calmodulin-
dependent protein kinase 
type II subunit delta E9PF82 43 
ATP binding 
site 1.74 ± 0.55 
MAP2K4  
Dual specificity mitogen-
activated protein kinase 
kinase 4 P45985 131 
ATP binding 
site 4.51 ± 0.28 
CSNK1A1 
Casein kinase I isoform 
alpha P48729 138 
catalytic 
domain Infinity 
CSNK2A1 
Casein kinase II subunit 
alpha P68400 158 
catalytic 
domain Infinity 
MAP3K2  
Mitogen-activated protein 
kinase kinase kinase 2 Q9Y2U5 485 
catalytic 
domain Infinity 
MAP3K3  
Mitogen-activated protein 
kinase kinase kinase 3 Q99759 491 
catalytic 
domain Infinity 
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MAP4K4  
Mitogen-activated protein 
kinase kinase kinase kinase 
4 G5E948 155 
catalytic 
domain Infinity 
MINK1  Misshapen-like kinase 1 
 
Q8N4C8 155 
catalytic 
domain Infinity 
NEK9 
Serine/threonine-protein 
kinase Nek9 Q8TD19 178 
catalytic 
domain Infinity 
STK24  
Serine/threonine-protein 
kinase 24 Q9Y6E0 158 
catalytic 
domain Infinity 
STK38 
Serine/threonine-protein 
kinase 38 Q15208 118 
ATP binding 
site Infinity 
STK38L 
Serine/threonine-protein 
kinase 38-like Q9Y2H1 119 
ATP binding 
site Infinity 
TNIK 
TRAF2 and NCK-interacting 
protein kinase Q9UKE5 155 
catalytic 
domain Infinity 
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CHARTER 5. HUMAN KINOME INTERACTOME 
PROFILING IN SKELETAL MUSCLE INSULIN 
RESISTANCE 
5.1 Introduction 
Protein kinases catalyze phosphorylation, one of the most important PTMs, 
which serves as a switch to turn “on” and “off” of molecular functions. In most of 
the cases, phosphorylated proteins (adding a phosphate group) become active or 
“on” mode, dephosphorylated proteins (removing a phosphate group) become 
inactive or “off” mode. Hence, protein kinases play essential roles in cell signal 
transduction and biological process, such as insulin signaling, MAP kinase 
signaling and glucose metabolic process. Protein kinases not only are key 
regulators for downstream substrate proteins but also highly regulated by 
phosphorylation; as a result, protein kinases are phosphorylated by other kinases 
or themselves (also known as autophosphorylation). For example, protein kinase 
B (or AKT) is highly regulated by upstream kinases, such as PDK1 and 
mTOR/Rictor, which phosphorylate AKT at Thr308 and Ser473 (Tsuchiya, Kanno, & 
Nishizaki, 2014). Receptor tyrosine kinases (i.e., EGFR) typically undergo 
autophosphorylation where ligand binding leads EGFR dimerization and multiple 
tyrosine residues are phosphorylated by EGFR (Bae & Schlessinger, 2010). 
Therefore, intracellular protein-protein interactions of kinase-substrate complexes 
and kinase-kinase complexes are primarily means but not limited to 1) cell 
signaling events, such as promotion or inhibition of each other’s activity; 2) 
transport across membranes, such as cytoplasm to nucleus transport; 3) protein 
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degradation, such as ubiquitination. Dysregulation of protein-protein interactions 
involving protein kinases might lead to cell signaling malfunction and diseases, 
such as insulin resistance and T2D; nonetheless, large scale profiling of active 
kinome interaction partners in human skeletal muscle insulin resistance remains 
unreported.  Here, we hypothesized that abnormalities of functional kinome 
interactome may exist in skeletal muscle of obese insulin resistant participants 
compared to lean healthy insulin sensitive subjects. We developed a new activity-
based functional kinome enrichment platform coupling with quantitative proteomics 
to globally enrich and quantify interaction partners of active kinases in human 
skeletal muscle in lean controls and obese insulin resistant participants.   
5.2 Materials and Methods 
5.2.1 SILAC labeled primary cultured human skeletal muscle cells 
Ten to fifteen mg of each human muscle biopsy from two lean healthy and 
two obese insulin resistance subjects were used to generate primary cultured 
human skeletal muscle cells. Method used was the same as described in 4.2.1. 
The primary cells were SILAC labeled with two heavy isotopic labeled amino 
acids: L-Lysine-2HCl, 4,4,5,5-D4 (Lys4, which is 4 Da heavier than neutral 
lysine) and L-Arginine-HCl, 13C6, 15N4 (Arg10, which is 10 Da heavier than neutral 
arginine).  Method used was the same as described in 4.2.2. 
5.2.2 Active protein kinases enrichment for functional kinome interactome  
Around 120–150 mg frozen muscle biopsy of each sample from 8 lean 
control (LC) and 8 obese insulin resistance (OBi) participants, and SILAC labeled 
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skeletal muscle cells as mentioned above were homogenized using a Next 
Advance Bullet Blender and lysed by Pierce IP Lysis Buffer with 8M urea and 
Halt™ Protease/Phosphatase Inhibitor Cocktail. Protein concentration was 
measured by Bradford protein assay, where Coomassie blue plus Kit with standard 
was used for this assay. For each sample 2.0 mg tissue lysate spiked-in with 1.0 
mg SILAC cell lysate (four cell lines from 2 LC and 2 OB were pooled first) was 
accurately aliquoted. Then the mixed lysate went through Zeba™ Spin Desalting 
Columns, 7K MWCO, 5mL to remove all the endogenous ATP. The filtrate lysate 
of 8 LC and 8 OBi were diluted with Reaction buffer into 2mg/mL, and incubated 
with 10 μL of 1M MgCl2 at room temperature for 1 minute. Before the probe labeling, 
each sample was evenly divided into two portions, one portion for real kinome 
interactome enrichment while the other portion served as negative control (without 
probe labeling to filter out non-specific binding proteins that are not labelled by the 
probe but pulled down by streptavidin agarose resin).  The portion for enrichment 
was labeled with 10μM ActivX™ Desthiobiotin-ATP incubation at room 
temperature for 10 minutes, whereas the negative controls were incubated with 10 
μL ddH2O for 10 minutes. The probe labeled lysate and negative control were 
incubated with 50μL of 50% high capacity streptavidin agarose resin slurry for 1 
hour at room temperature on a mixing rotator; subsequently, the resin was washed 
3 times with lysis buffer, 3 times with PBS, and 3 times with LCMS-grade water. 
The agarose resin slurry with pulled down proteins were incubated with 10mM 
dithiothreitol (DTT) for 30 minutes at 55 °C and 50mM iodoacetamide (IAA) 
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incubation for 30min at room temperature in dark. “On-beads” digestion was 
performed with 2μg protease MS grade trypsin incubation for 16 hours at on a 
thermo shaker at 37°C. The resulting peptides were dried with a speedvac, and 
were desalted with Zipclean tips and reconstituted with 0.1% TFA in water for 
HPLC-ESI-MS/MS analysis. Noted that all the catalog number and vendor 
company are the same as described in 4.2.3 
5.2.3 HPLC-ESI-MS/MS analysis 
As described in 4.2.4 
5.2.4 Database search  
As described in 4.2.5 
5.2.5 Bait active protein kinome and its interactome identification and 
quantification 
In the desthiobiotin K peptides file generated from MaxQuant software 
package, which provides sequence of modified peptides with lysine sites and their 
intensity, a bait kinase has to be identified with at least one of the two lysine 
residues (#1 in ATP binding site and #2 in catalytic domain) on the desthiobiotin 
modified lysine site. Because of the high selectivity and sensitivity of the ATP probe, 
all the bait protein kinases were considered as in their active form. In order to unveil 
true interaction partners of functional kinome, the identified proteins other than bait 
proteins (i.e., active kinases in this case) must satisfied the following three rigorous 
criteria: 1) the protein must be identified with minimum two unique peptides; 2) the 
protein must be identified with light labeled peak area (PA) in at least half of the 
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kinome interaction partner enrichments (i.e., ≥8 biopsy samples); 3) those proteins 
must have an enrichment ratio (Kinome IP/negative control IP) of >10. In order to 
calculate the enrichment, the PA for each protein identified was normalized against 
Universal SILAC:  the heavy labeled proteins identified in at least 8 out of 16 
samples were used as “Universal” internal standard, and the total peak of the 
SILAC labeled lysine sites were calculated in each sample. Then, the peak area 
of each kinase (PAi) was normalized by the sum peak area of universal heavy 
labeled proteins in the same sample: 
Norm ∶  𝑖 =
PA𝑖
Total peak area of SILAC labeled heavy proteins identified in ≥ 8 samples
 
 Due to the sensitivity of this platform, non-specific binding partners may 
result in high discover rate of false-positive. Therefore, we employed negative 
controls without probe labeling to eliminate nonspecific binding accumulated in the 
experiment process. The negative control concepts have been widely used and 
accepted for protein-protein interaction partner identification in our previous work 
(Caruso, Ma, Msallaty, Lewis, Seyoum, Al-janabi, Diamond, Abou-Samra, Hojlund, 
et al., 2014; Caruso et al., 2015; X. Zhang et al., 2016). For each sample, the 
enrichment ratio was calculated as followed: the average of SILAC normalized PA 
from real enrichment pull down experiment was divided by the average of SILAC 
normalized PA from negative control. It is noted that if zero identification in 
negative control, then the enrichment ratio of that protein was manually assigned 
as infinity. The calculation formula of enrichment ratio listed below:  
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   Enrichment_Ratio ∶  𝑖 =
Average_Norm: 𝑖_IP
Average_Norm: 𝑖_control
 
In order to quantify relative protein abundance of the kinome interaction 
partners, the PAj of each partner protein was normalized against PAj of total bait 
kinases in the same sample. This normalization approach for protein-protein 
interaction study has been demonstrated and employed in either quantitative 
proteomics or western blotting (Caruso, Ma, Msallaty, Lewis, Seyoum, Al-janabi, 
Diamond, Abou-Samra, Hojlund, et al., 2014; Caruso et al., 2015; Wepf, Glatter, 
Schmidt, Aebersold, & Gstaiger, 2009; X. Zhang et al., 2016). The normalization 
formula listed below:  
   Norm ∶  𝑗 =
PAj
PAj_𝑡𝑜𝑡𝑎𝑙 𝑏𝑎𝑖𝑡 𝑘𝑖𝑛𝑎𝑠𝑒𝑠
 
To determine the significantly changed partners, a fold change of OBi/LC 
greater than 1.5 or less than 0.67 was required, subsequently, p-value of 
independent two-side t-test must be less than 0.05.  
5.2.6 Bioinformatics 
As described in 4.2.7 
5.3 Results 
5.3.1 Kinome interaction partners in human skeletal muscle insulin 
resistance 
To determine the true interaction partners of functional kinome in human 
skeletal muscle insulin resistance, a rigorous identification and quantification 
procedure was designed in figure 5-1. We first identified 1791 proteins with 
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minimum two unique peptides and 0.01 false discovery rate (FDR) which has been 
widely accepted for quantitative proteomics analysis for interaction partners 
discovery (Wepf et al., 2009).  Furthermore, we categorized 18 protein kinases, 
being identified with at least one conserved lysine residue, which served as bait 
proteins (Table 5-1); the rest 1773 proteins were potential prey proteins for the 18 
active kinases. Then, in order to eliminate the nonspecific binding proteins, we 
filtered 1580 proteins with enrichment ratios greater than 10. The true interaction 
partners also need to be identified in at least half sample size (i.e.,  ≥ 8 muscle 
biopsies); as a result, there were 616 proteins assigned as true interaction proteins 
which were, based on our literature search, the first functional kinome interactome 
in human skeletal muscle. The active kinases or active conformation of the kinases 
are the real “players” in cellular functions because inactive kinases lose their 
intrinsic enzyme activity or with very low catalytic level (Chihara-Nakashima, 
Hashimoto, & Nishizuka, 1977; Phillips, Aponte, Covian, & Balaban, 2011; Ward 
& O'Brian, 1992); therefore, the proteins interacted with active kinases are 
important to understand the abnormalities of cell signaling and molecular function 
in muscle insulin resistance.  
First, we analyzed the 18 bait protein kinases which are the key modulators 
in cell signal transduction. Among the 18 protein kinase, as expected from specific 
aim 1, only one tyrosine kinase (Tyrosine-protein kinase CSK) was enriched, and 
the other 17 kinases were all serine/threonine kinases. As we know, each 
individual kinase may involve in multiple cell signaling pathway but, for most well 
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studied kinases, has a few primary focuses; for example, AMPK1 is mainly 
involved in AMPK pathway. Based on Uniprot and Gene Ontology databases, we 
assigned the 18 protein kinases in 5 primary signaling pathways but 4 kinases 
were not being assigned to any known signaling pathway based on the database 
search (Figure 5-2). There were 5 protein kinases were mapped in the ERK1/2 
pathway, which is also part of typical insulin signaling and mTOR signaling 
pathway, and 3 kinases involved in AMPK pathway, which is also part of mTOR 
signaling; two kinases participate in Wnt signaling; two kinases were assigned to 
JNK pathway and two kinases involved in p38 MAPK signaling. Furthermore, a 
biofunction analysis was performed on these 18 kinases (Figure 5-3). As we 
expected 18 kinases showed phosphotransferase activity; in contrast, three 
kinases displayed tyrosine kinase activity, but only 1 out of 3 was tyrosine kinase 
and the other 2 kinases were serine/threonine kinases, serine/threonine-protein 
kinase Nek6 (NEK6) and dual specificity mitogen-activated protein kinase kinase 
6 (MAP2K6 or MEK6). MEK6 has been reported to phosphorylate both serine and 
tyrosine residue on the p38 MAP kinases (Visconti et al., 2000). Due to the limited 
number of bait kinases, a large bioinformatics analysis may not show significance 
on many biofunctions, but these 18 kinases did involve in multiple foundational cell 
signaling (Figure 5-2) which is highly related to insulin signaling (e.g., ERK1/2 
pathway) and glucose uptake (e.g., AMPK pathway).  
Second, we analyzed the 616 kinome interaction partners that directly or 
indirectly bind to the bait active kinases. Noted that protein binding could be transit; 
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therefore, this analysis may not contain the complete map of the interaction 
proteome. Also, non-protein kinases and atypical kinases (without kinase core) or 
other typical kinases, which are either in inactive conformation (“closed” ATP 
binding site) or their ATP binding sites were blocked in the kinase-kinase 
complexes, were also considered as interaction partners. Therefore, out of the 616 
interaction partners, we identified 26 protein kinases (including 1 regulatory 
subunit), 12 non-protein kinases, 2 protein phosphatases and 2 protein 
phosphatase regulatory subunits (Table 5-2), such as MAPK1. MAPK3, tyrosine-
protein kinase Fyn (FYN), tyrosine-protein kinase Yes (YES1), integrin-linked 
protein kinase (ILK), cAMP-dependent protein kinase catalytic subunit alpha 
(PRKACA), cGMP-dependent protein kinase 1 (PRKG1), hexokinase-1 (HK1), 
TP53-regulating kinase (TP53RK), serine/threonine-protein phosphatase PP1-
alpha catalytic subunit (PPP1CA), protein phosphatase 1 regulatory subunit 12A 
(PPP1R12A) and serine/threonine-protein phosphatase 2A 55 kDa regulatory 
subunit B alpha isoform (PPP2R2A). Our finding indicated that dozens of kinase-
kinase interactions exist in human skeletal muscle.  
Next, we conducted cell signaling pathway (Figure 5-4) and biofunction 
analysis (Figure 5-5) on the 616 kinome interaction partners using IPA and David 
bioinformatics online source integrating GOTERM, KEGG and Recatome 
databases.  Diabetes pathway (from reactome database) was significantly 
enriched with highest -log (p-value) at 15.44, and it covers 72 proteins that may 
contribute to the pathogenesis of diabetes. For example, cAMP-dependent protein 
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kinase type II-alpha regulatory subunit (PRKAR2A), (cAMP-dependent protein 
kinase catalytic subunit alpha (PRKACA) and ras-related protein Rap-1b (RAP1B) 
was categorized into diabetes pathway. Besides diabetes pathway, mTOR 
signaling was also enriched with very high significant level. As we described above, 
mTOR is a critical pathway regulates multiple key players that might involve in 
insulin resistance and T2D, such as MAPK1, Growth factor receptor-bound protein 
2 (GRB2), 40S ribosomal protein S3 (RPS3), 5'-AMP-activated protein kinase 
subunit beta-2 (PRKAB2), eukaryotic translation initiation factor 3 subunit A (EIF3A) 
and 40S ribosomal protein S6 (RPS6). Furthermore, insulin signaling pathway with 
20 protein interaction partners (from KEGG database) was significantly enriched 
as well. In addition, multiple essential signaling pathways were also significantly 
enriched, including p70S6K signaling (downstream of mTOR), Wnt signaling, ILK 
signaling, and apoptosis related pathway. Figure 5-4 illustrates the top 8 identified 
pathways related but not limit to insulin signaling, cell growth and programmed 
death, and diabetes.  
The biofunction analysis of the kinome interactome indicated that protein 
folding, proteasome, positive/negative regulation of ubiquitination and regulation 
of cytoskeleton were highly enriched. These biofunctions are key molecular 
processes for protein synthesis and degradation, and cytoskeleton remodeling. 
Beyond those, glucose, pyruvate and glycogen metabolism play the central roles 
in glucose homeostasis; similarly, fatty acid and lipid metabolism are critical 
biological processes for lipid homeostasis. Taken all the biofunction analysis 
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results, the kinome interaction partners participate in maintaining proteins, glucose, 
and lipids balances in skeletal muscle, and might be contribute to abnormal 
metabolism in obese individuals with insulin resistance.  
5.3.2  Significantly changed functional kinome interaction partners in 
skeletal muscle insulin resistance 
Importantly, we identified 135 kinome interaction proteins with a fold change 
greater than 1.5 (i.e., 83 proteins increased in OBi) or less than 0.67 (i.e., 52 
proteins decreased in OBi) and also with significant p-value from independent two-
side student t-tests (p < 0.05) comparing OBi with lean subjects. Of the 135 
proteins, 131 were only identified in kinome IPs but not in negative control IPs, 
which suggested the high confidence of the results.  The 135 significantly changed 
partners might be responsible for abnormal molecular function and cell signaling 
caused by insulin resistance in skeletal muscle (Table 5-3).  
Based on the pathway analysis for the interaction partners, we identified 20 
proteins involved in the insulin signaling pathway, which is one of the most studied 
pathways for abnormal molecular function and cell signaling related to insulin 
resistance and T2D. We color coded insulin signaling pathway (downloaded from 
http://www.kegg.jp) with identified partners in that pathway according to their 
difference in kinome interaction; interestingly, out of the 20 kinome interaction 
partners, 17 proteins remained unchanged and only 3 proteins (i.e., RPS6, 
PRKAB2 and PRKAR2A) had significantly increased association to the active 
kinases (Figure 5-7). Also, we mapped 16 interaction proteins in the MAPK 
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signaling pathway (downloaded from http://www.kegg.jp); similarly,13 proteins 
remained intact and 3 partners showed enhanced interactions with active kinases 
in OBi, which were heat shock-related 70 kDa protein 2 (HSPA2), Voltage-
dependent L-type calcium channel subunit beta-1 (CACNB1) and MAPT (Figure 
5-8). Furthermore, two increased partners and 4 decreased in OBi compared to 
LC were mapped into ILK pathway (downloaded from IPA software package) which 
was significantly enriched in the pathway analysis for kinome interactome (Figure 
5-8). In addition, two protein kinases with attenuated interactions to active kinases 
in OBi were not categorized in any pathway above: YES1 (reduced 3.73 folds in 
OBi) and TP53RK (reduced 2.67 folds in OBi), which play central roles in cell cycle, 
cytokine responsive pathway and tumor cell differentiation and proliferation. In 
addition, no phosphatase was identified with significant changes. 
We performed biofunction analysis (Figure 5-6), which suggested abnormal 
protein degradation and synthesis, apoptosis and cytoskeleton dynamics may 
contribute to the pathogenesis of insulin resistance in human skeletal muscle. Of 
interest, 5 out of the 6 proteins (i.e.,  PSMA1, PSMD14, PSMD11, PSMC3, PSMD7) 
regulated ubiquitination were significantly increased, which might indicate a trend 
for up-regulated ubiquitination in OBi.  
To elucidate the protein-protein interaction of the 18 active bait kinases and 
their 135 significant interaction partners, an interaction network was developed 
using IPA with mapping parameter set at maximum 70 molecules per network 
(Figure 5-6). We mapped 15 out of the 18 bait protein kinases (highlighted in 
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yellow), 6 increased kinome interaction partner (highlighted in red) and 7 
interaction proteins that showed decreased trend (highlighted in green) in the 
network. The central core protein is ERK1/2, which has been identified as an 
interaction partner of kinome, but did not show significant change. In the network, 
we noticed a few proteins in the center were closely interacted with multiple 
kinases (e.g., ERK1/2), such as integrin-linked protein kinase (ILK), vimentin (VIM), 
RPS6, and microtubule-associated protein tau (MAPT).  
5.4 Discussion  
Intracellular protein-protein interactions mediated cell signal transduction, 
protein transport, endocytosis and exocytosis of signaling molecules (e.g., insulin 
granule exocytosis) have been widely accepted and recognized, and protein 
kinases are known active reaction modules that interact with dozens of substrates 
or regulatory proteins. High-throughput methods for protein-protein interaction 
analysis have been broadly used, such as co-immunoprecipitation which allows 
bait protein binding as well as the interaction proteins bound to the bait. However, 
the typical Co-IP targets one bait protein which is specifically against the antibody 
conjugated to the protein A/G beads. Here, we present an ATP probe pull-down 
assay that enriches dozen of active protein kinases and their interaction partners 
using activity-based ATP probes instead protein antibodies. Coupling high 
resolution mass spectrometry with the ATP probe, we identified the first functional 
kinome interactome (616 proteins) in the human skeletal muscle insulin resistance, 
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which provided a global picture of kinase interaction complexes including kinase-
substrate, kinase-kinase, etc.  
5.4.1 Insulin signaling pathway 
Insulin signaling pathway is the central and most studied pathway that 
affects insulin sensitivity and glucose metabolism; and dysregulation of insulin 
signaling may result in insulin resistance and impaired insulin stimulated glucose 
uptake. In this study, we identified and quantified 20 kinome interaction partners 
involved in insulin signaling (Figure 5-8); and majority of them have unchanged 
association with core active kinases in OBi. For example, the interaction to active 
kinases for PPP1CA/PPP1CC (two catalytic subunits of protein phosphatase-1), 
phosphorylase b kinase regulatory subunit alpha (PHKA1), glycogen 
phosphorylase (PYGB) which directly interact with each other (based on KEGG’s 
data), remained the same in OBi. Also, GRB2 and ERK1 did not show significant 
difference in their interaction to active kinases between LC and OBi. However, 
multiple proteins in the insulin signaling pathway exhibited increased interaction 
with active kinome, such as RPS6, PRKAB2 and PRKAR2A. Of interest, PRKAB2 
(AMPK Subunit Beta-2), a non-catalytic subunit of AMPK1/2, which has been 
shown down-regulated trend in our kinome profiling in Aim 1, has been reported 
as a scaffold to assemble the AMPK complex which includes α (catalytic), β, and 
γ subunits (Scott et al., 2004; Xiao et al., 2007). The molecular function of β subunit 
of AMPK is far from well understood, and it is known that subcellular localization 
and PTMs of AMPK can influence its activity (Salt et al., 1998; Warden et al., 2001). 
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Qi et al., reported that ubiquitination of AMPK β subunit exert negative regulation 
of AMPK1 activity in brown adipose tissue from mice (Qi et al., 2008); furthermore, 
they proposed that elevated inflammation in the adipose tissue may lead to down-
regulated AMPK activity via increased PRKAB2 ubiquitination. In our study, we 
also demonstrated up-regulated ubiquitination in OBi through the biofunction 
analysis of the 135 significantly changed interaction partners. Therefore, our 
finding suggested that increased PRKAB2 association with active kinome might 
inhibit AMPK1 activity via the ubiquitin-proteasome protein degradation. It is noted 
that researchers (Rubio, Vernia, & Sanz, 2013) also reported that sumoylation of 
PRKAB2 enhanced AMPK activity, but they pinpointed that ubiquitination and 
sumoylation shared the same catalytic lysine residue on PRKAB2, so these two 
PTMs were competitive binding. Combining our data showing increased regulation 
of ubiquitination, it seems that PRKAB2 might be a negative regulator of AMPK 
activity in addition to be a scaffold subunit.   
5.4.2 MAPK signaling pathway 
MAPK signaling (Figure 5-9), including three sub-pathways: ERK1/2 
signaling, JNK signaling and p38 MAPK signaling, is mainly responsible for cell 
survival, differentiation and proliferation, and inflammation. We identified 16 
kinome interaction partners assigned to MAPK signaling, primarily on ERK1/2 
signaling (14 partners). GTPase HRas (HRAS) was identified as unchanged 
partners, and Ras is one of the most important modulators in ERK signaling. 
Additionally, two RafB regulators, Rap1 and PKA, were also identified, and the 
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quantified results implied no significant change of Rap1 and PKA when interacting 
with functional kinome. Combined with our results in specific aim 1 that EGFR, 
RafB, MEK1, MEK2, ERK2 displayed no changed kinase activity, it seems that 
ERK1/2 signaling pathway might remain intact in the insulin resistant skeletal 
muscle, which is in agreement with some literature (Cusi et al., 2000; Krook et al., 
2000). 
Interestingly, we found three kinome interaction partners (HSPA2, CACNB1 
and MAPT) exhibited significant increased binding to active kinases, of which 
CACNB1 displayed mixed kinome interaction (another subunit CACNA1S showed 
no change). HSPA2, belonged to HSP70 family, is one of the most universal 
molecular chaperones that assisting protein folding (Gehrmann et al., 2005; M. 
Hantschel et al., 2000), and dysregulation of HSP70 leads to various diseases, 
such as diabetes (Pockley, Henderson, & Multhoff, 2014). Growing evidence 
indicates increased serum HSP70 level in diabetic patients (Garamvolgyi, 
Prohaszka, Rigo, Kecskemeti, & Molvarec, 2015; Nakhjavani et al., 2010; Pagetta, 
Folda, Brunati, & Finotti, 2003); however, its cellular mechanism in skeletal muscle 
insulin resistance and T2D remains unknown. Previous data suggested that 
HSP70 promoted muscle regeneration after injury and was responsive to 
inflammatory cytokines. Emerging data reports that insulin resistance and obesity 
induce inflammation in skeletal muscle (Hotamisligil, 2006; Lumeng & Saltiel, 2011; 
McNelis & Olefsky, 2014; Osborn & Olefsky, 2012), and another theory of skeletal 
muscle inflammation is that immune cells, secreting pro-inflammatory cytokines, 
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are accumulating in myotubes (Wu & Ballantyne, 2017). Another study reported 
that HSP70 activated T cells in autoimmune arthritis (Wieten et al., 2010), which 
supports that the positive correlation between HSP70 and insulin resistance via an 
inflammatory manner. The current finding that increased HSPA2 association with 
functional kinome in OBi further supports HSP70’s role in skeletal muscle insulin 
resistance.  
5.4.3 ILK signaling pathway 
Integrin-linked kinase catalyzes variety of intracellular and extracellular 
functions, such as cell migration and proliferation, through integrin which is a 
transmembrane receptors. In this study (Figure 5-10), we observed decreased 
kinome interaction with ILK, myosin heavy chain 1 (MYH1), vimentin (VIM), actin, 
cytoplasmic 2 (ACTG1), and increased kinome association level with nascent 
polypeptide-associated complex alpha subunit (NANA), fibronectin 1(FN1). Of 
interest, early work reported that ILK is necessary for PI3K mediated AKT signaling, 
and ILK directly phosphorylates GSK3 (Delcommenne et al., 1998). Recent work 
suggested that decreased glucose uptake and insulin sensitivity in ILK deficiency 
mice in a GLUT4-dependent manner (Hatem-Vaquero et al., 2017). Based on our 
literature search, only one study focused on the ILK function in development of 
muscle insulin resistance, which was done in mice (Kang et al., 2016), nonetheless, 
reduced kinome interaction with ILK has not been reported.  
5.5 Summary 
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We identified 616 functional kinome interaction partners in human skeletal 
muscle from 8 lean healthy and 8 obese insulin resistant participants, which is the 
largest human kinome interactome to date. Among the 616 interaction partners, 
385 has a fold change > 1.5 or <0.67.  Out of these 385 kinome interaction partners, 
135 displayed significantly difference between the two groups (p-value < 0.05). 
The kinome interatome participate in various cell signaling pathways (i.e., diabetes 
pathway, mTOR pathway, insulin signaling pathway, etc.) and biofunctions (i.e., 
protein synthesis and degradation, cytoskeleton dynamics, and apoptosis).  
Notably, we developed this ATP probe pull-down platform coupling with 
quantitative proteomics, which allowed us to globally profile protein interaction 
partners of dozens of active kinases simultaneously. However, the obvious 
limitation was that interaction partners cannot be assigned to one particular kinase.  
Nonetheless, using this approach, we generated the 1st active kinome interactome 
profile in skeletal muscle of lean heathy individuals, and how it is differ in obese 
insulin resistant subjects, which offers new information on molecular mechanism 
of skeletal muscle insulin resistance. 
 
 
 
 
 
 
 
 
128 
 
 
 
 
 
 
 
Figure 5-1. Flowchart of kinome interactome identification and quantification 
procedure. 
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Figure 5-2. Primary cell signaling pathways assigned for the 18 bait kinases. 
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Figure 5-3. Biofunction analysis of the 18 bait kinases. Data label on the bar 
represents the number of bait protein kinases participated in that biofunction. 
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Figure 5-4. Signaling pathway analysis of the 616 functional kinome 
interaction partners. Data label on the bar represents the number of protein 
interaction partners participated in that pathway. 
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Figure 5-5. Biofunction analysis of the 616 functional kinome interaction 
partners. Data label on the bar represents the number of protein interaction 
partners participated in that biofunction.  
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Figure 5-6. Biofunction analysis of the 135 significantly changed functional 
kinome interaction partners. Data label on the bar represents the number of 
significantly changed protein interaction partners participated in that biofunction.  
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Figure 5-7. Interaction network of the 18 bait protein kinases and 
significantly changed functional kinome interaction partners. Solid line is 
indicating direct interactions and dashed line is indicating indirect interactions. 
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Figure 5-8. Color-coded insulin signaling pathway of kinome interaction 
partners according to their differences in LC and OBi. Pathway map was 
downloaded from KEGG. 
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Figure 5-9. Color-coded MAPK signaling pathway of kinome interaction 
partners according to their differences in LC and OBi. Pathway map was 
downloaded from KEGG. 
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Figure 5-10. Color-coded ILK signaling pathway of significantly changed 
kinome interaction partners according to their differences in LC and OBi. 
Pathway map was adapted from IPA. 
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Table 5-1.  Identified active protein kinase lysine sites (assigned to 18 
kinases) served as bait proteins in kinome interactome profiling. 
Gene 
Name 
Protein Name 
Modified 
sequence 
Desthio
biotin K 
positio
ns 
within 
protein
s 
Binding K 
type 
CAMK2
D 
Calcium/calmodulin-dependent 
protein kinase type II subunit delta 
IPTGQEYAAK(de)II
NTK 43 
ATP binding 
Site 
CAMK2
G 
Calcium/calmodulin-dependent 
protein kinase type II subunit 
gamma 
TSTQEYAAK(de)II
NTK 43 
ATP binding 
Site 
CDK5 Cyclin-dependent kinase 5 DLK(de)PQNLLINR 128 
Catalytic 
Domain 
CSK Tyrosine-protein kinase CSK 
VSDFGLTK(de)EAS
STQDTGKLPVK 337 
Catalytic 
Domain 
MAP2K
1 
Dual specificity mitogen-activated 
protein kinase kinase 1 K(de)LIHLEIKPAIR 97 
ATP binding 
Site 
MAP2K
1 
Dual specificity mitogen-activated 
protein kinase kinase 1 
DVK(de)PSNILVNS
R 192 
Catalytic 
Domain 
MAP2K
2 
Dual specificity mitogen-activated 
protein kinase kinase 2 K(de)LIHLEIKPAIR 101 
ATP binding 
Site 
MAP2K
2 
Dual specificity mitogen-activated 
protein kinase kinase 2 
DVK(de)PSNILVNS
R 196 
Catalytic 
Domain 
MAP2K
3 
Dual specificity mitogen-activated 
protein kinase kinase 3 DVK(de)PSNVLINK 192 
Catalytic 
Domain 
MAP2K
3 
Dual specificity mitogen-activated 
protein kinase kinase 3 
HAQSGTIMAVK(d
e)R 93 
ATP binding 
Site 
MAP2K
4 
Dual specificity mitogen-activated 
protein kinase kinase 4 DIK(de)PSNILLDR 231 
Catalytic 
Domain 
MAP2K
4 
Dual specificity mitogen-activated 
protein kinase kinase 4 
PSGQIM(ox)AVK(d
e)R 131 
ATP binding 
Site 
MAP2K
6 
Dual specificity mitogen-activated 
protein kinase kinase 6 
LSVIHRDVK(de)PS
NVLINALGQVK 181 
Catalytic 
Domain 
MAP2K
6 
Dual specificity mitogen-activated 
protein kinase kinase 6 
M(ox)RHVPSGQI
M(ox)AVK(de)R 82 
ATP binding 
Site 
NEK6 
Serine/threonine-protein kinase 
Nek6 DIK(de)PANVFITA 174 
Catalytic 
Domain 
NEK7 
Serine/threonine-protein kinase 
Nek7 
DIK(de)PANVFITA
TGVVK 163 
Catalytic 
Domain 
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NEK9 
Serine/threonine-protein kinase 
Nek9 LGDYGLAK(de)K 81 
ATP binding 
Site 
PRKAA1 
5'-AMP-activated protein kinase 
catalytic subunit alpha-1 VAVK(de)ILNR 56 
ATP binding 
Site 
PRKAA2 
5'-AMP-activated protein kinase 
catalytic subunit alpha-2 VAVK(de)ILNR 45 
ATP binding 
Site 
RPS6KA
1 
Ribosomal protein S6 kinase alpha-
1 
DLK(de)PENILLDEE
GHIK 189 
Catalytic 
Domain 
RPS6KA
2 
Ribosomal protein S6 kinase alpha-
2 
DLK(de)PENILLDEE
G 186 
Catalytic 
Domain 
RPS6KA
3 
Ribosomal protein S6 kinase alpha-
3 
DLK(de)PENILLDEE
GH 195 
Catalytic 
Domain 
ULK3 
Serine/threonine-protein kinase 
ULK3 
NISHLDLK(de)PQN
ILLSSLEKPHLK 139 
Catalytic 
Domain 
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Table 5-2.  Kinases and phosphatases identified as functional kinome 
interaction partners. 
Gene 
name Protein name Category 
ALDH18A
1 Glutamate 5-kinase Non-protein kinase 
BCKDK 
[3-methyl-2-oxobutanoate dehydrogenase 
[lipoamide]] kinase, mitochondrial Non-protein kinase 
CAMK2A 
Calcium/calmodulin-dependent protein kinase type II 
subunit alpha Protein kinase 
CAMK2B 
Calcium/calmodulin-dependent protein kinase type II 
subunit beta Protein kinase 
CMPK1 UMP-CMP kinase Non-protein kinase 
CSNK2A1 Casein kinase II subunit alpha Protein kinase 
CSNK2A2 Casein kinase II subunit alpha Protein kinase 
EIF2AK2 
Interferon-induced, double-stranded RNA-activated 
protein kinase Protein kinase 
FAM20B Glycosaminoglycan xylosylkinase Non-protein kinase 
FN3K Fructosamine-3-kinase Non-protein kinase 
FN3KRP Ketosamine-3-kinase Non-protein kinase 
FYN Tyrosine-protein kinase Fyn Protein kinase 
HK1 Hexokinase-1 Non-protein kinase 
ILK Integrin-linked protein kinase Protein kinase 
MAPK1 Mitogen-activated protein kinase 1 Protein kinase 
MAPK3 Mitogen-activated protein kinase 3 Protein kinase 
MLTK Mitogen-activated protein kinase kinase kinase MLT Protein kinase 
MYLK Myosin light chain kinase, smooth muscle Protein kinase 
MYLK2 Myosin light chain kinase 2, skeletal/cardiac muscle Protein kinase 
NME1 Nucleoside diphosphate kinase A Protein kinase 
NME2 Nucleoside diphosphate kinase B Protein kinase 
PANK4 Pantothenate kinase 4 Non-protein kinase 
PFKL 6-phosphofructokinase, liver type Non-protein kinase 
PGAM5 
Serine/threonine-protein phosphatase PGAM5, 
mitochondrial Protein phosphatase 
PHKG2 
Phosphorylase b kinase gamma catalytic chain, 
testis/liver isoform Non-protein kinase 
PPP1CA 
Serine/threonine-protein phosphatase PP1-alpha 
catalytic subunit Protein phosphatase 
PPP1R12
A Protein phosphatase 1 regulatory subunit 12A 
Protein phosphatase 
regulatory subunit  
PPP2R2A 
Serine/threonine-protein phosphatase 2A 55 kDa 
regulatory subunit B alpha isoform 
Protein phosphatase 
regulatory subunit  
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PRKAB2 5-AMP-activated protein kinase subunit beta-2 Protein kinase 
PRKACA 
cAMP-dependent protein kinase catalytic subunit 
alpha Protein kinase 
PRKACB 
cAMP-dependent protein kinase catalytic subunit 
beta Protein kinase 
PRKAG1 5-AMP-activated protein kinase subunit gamma-1 Protein kinase 
PRKAR2A 
cAMP-dependent protein kinase type II-alpha 
regulatory subunit 
Protein kinase regulatory 
subunit  
PRKG1 cGMP-dependent protein kinase 1 Protein kinase 
PRPS1 Ribose-phosphate pyrophosphokinase 1 Non-protein kinase 
PRPS1L1 Ribose-phosphate pyrophosphokinase 3 Non-protein kinase 
SLK STE20-like serine/threonine-protein kinase Protein kinase 
STK24 Serine/threonine-protein kinase 24 Protein kinase 
STK38 Serine/threonine-protein kinase 38 Protein kinase 
STK38L Serine/threonine-protein kinase 38-like Protein kinase 
TP53RK TP53-regulating kinase Protein kinase 
YES1 Tyrosine-protein kinase Yes Protein kinase 
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Table 5-3.  135 significantly changed functional kinome interaction partners. 
Gene 
Name Protein Name Protein ID 
Mean of fold 
Change 
SEM of Fold 
Change 
ACOT9 
Acyl-coenzyme A thioesterase 9, 
mitochondrial Q9Y305 0.308 0.05 
ACSL3 Long-chain-fatty-acid--CoA ligase 3 O95573 0.186 0.04 
ACTG1 
Actin, cytoplasmic 2;Actin, 
cytoplasmic 2, N-terminally 
processed P63261 0.309 0.08 
AHCY Adenosylhomocysteinase P23526 0.260 0.02 
AHCYL2 
Putative adenosylhomocysteinase 
3;Adenosylhomocysteinase Q96HN2 0.336 0.07 
ALDH4A1 
Delta-1-pyrroline-5-carboxylate 
dehydrogenase, mitochondrial P30038 0.184 0.07 
ANXA1 Annexin A1;Annexin P04083 18.769 5.33 
ANXA6 Annexin;Annexin A6;Annexin A6NN80 4.926 1.23 
APOBEC2 
Probable C->U-editing enzyme 
APOBEC-2 Q9Y235 20.517 8.05 
ARPC3 
Actin-related protein 2/3 complex 
subunit 3 O15145 5.195 1.69 
ATP1B1 
Sodium/potassium-transporting 
ATPase subunit beta-1 P05026 4.363 0.90 
ATP2B1 
Plasma membrane calcium-
transporting ATPase 1 P20020 0.419 0.10 
ATP5H 
ATP synthase subunit d, 
mitochondrial O75947 7.243 2.77 
C14orf16
6 UPF0568 protein C14orf166 Q9Y224 55.310 21.12 
C1QBP 
Complement component 1 Q 
subcomponent-binding protein, 
mitochondrial Q07021 15.448 5.93 
C22orf28 tRNA-splicing ligase RtcB homolog Q9Y3I0 7.119 2.54 
CACNB1 
Voltage-dependent L-type calcium 
channel subunit beta-1 Q02641 16.592 6.12 
CAP2 
Adenylyl cyclase-associated protein 
2 P40123 11.697 4.13 
CAPRIN1 Caprin-1 Q14444 4.540 1.23 
CAPZA1 
F-actin-capping protein subunit 
alpha-1 P52907 0.083 0.01 
CBR1 Carbonyl reductase [NADPH] 1 P16152 4.371 0.75 
CCDC56 
Coiled-coil domain-containing 
protein 56 Q9Y2R0 17.046 12.06 
143 
 
 
 
CLIC4 
Chloride intracellular channel 
protein 4 Q9Y696 4.169 2.40 
CLPB 
Caseinolytic peptidase B protein 
homolog Q9H078 0.458 0.14 
CMPK1 UMP-CMP kinase P30085 6.667 2.32 
CYB5R1 NADH-cytochrome b5 reductase 1 Q9UHQ9 0.526 0.07 
DARS Aspartate--tRNA ligase, cytoplasmic P14868 0.340 0.06 
DPM1 
Dolichol-phosphate 
mannosyltransferase H0Y368 0.096 0.06 
DYNC1I2 
Cytoplasmic dynein 1 intermediate 
chain 2 Q13409 2.562 0.48 
ECHS1 Enoyl-CoA hydratase, mitochondrial P30084 7.039 2.18 
EEF1A1 Elongation factor 1-alpha 1 P68104 0.624 0.11 
EEF1A1P
5 
Putative elongation factor 1-alpha-
like 3 P68104 0.624 0.11 
EIF5A 
Eukaryotic translation initiation 
factor 5A-1 I3L504 12.005 4.01 
EIF5AL1 
Eukaryotic translation initiation 
factor 5A-1-like I3L504 12.005 4.01 
ERP29 
Endoplasmic reticulum resident 
protein 29 P30040 32.987 12.08 
F13A1 Coagulation factor XIII A chain P00488 0.078 0.04 
FAM98A Protein FAM98A Q8NCA5 31.981 7.90 
FHOD1 
FH1/FH2 domain-containing 
protein 1 Q9Y613 4.336 1.45 
FKBP3 
Peptidyl-prolyl cis-trans isomerase 
FKBP3 Q00688 25.973 11.24 
FN1 
Fibronectin;Anastellin;Ugl-Y1;Ugl-
Y2;Ugl-Y3 P02751 14.001 5.37 
GLIPR2 
Golgi-associated plant 
pathogenesis-related protein 1 Q9H4G4 0.266 0.14 
GLS 
Glutaminase kidney isoform, 
mitochondrial O94925 0.236 0.08 
GSTK1 Glutathione S-transferase kappa 1 Q9Y2Q3 3.789 0.76 
GSTM2 Glutathione S-transferase Mu 2 P28161 12.256 3.23 
H1F0 Histone H1.0 P07305 14.269 6.09 
HMGB1 High mobility group protein B1 P09429 15.483 7.99 
HNRNPR 
Heterogeneous nuclear 
ribonucleoprotein R O43390 6.550 1.27 
HRC 
Sarcoplasmic reticulum histidine-
rich calcium-binding protein P23327 3.003 0.62 
HSD17B1
0 
3-hydroxyacyl-CoA dehydrogenase 
type-2 Q99714 0.368 0.04 
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HSPA2 
Heat shock-related 70 kDa protein 
2 P54652 4.584 1.10 
HSPB2 Heat shock protein beta-2 Q16082 5.175 1.85 
IDH3G 
Isocitrate dehydrogenase [NAD] 
subunit gamma, mitochondrial P51553 0.191 0.09 
IKBIP 
Inhibitor of nuclear factor kappa-B 
kinase-interacting protein Q70UQ0 6.037 1.52 
ILK Integrin-linked protein kinase Q13418 0.449 0.16 
ITGA7 Integrin alpha-7 Q13683 0.133 0.07 
JPH1 Junctophilin-1 Q9HDC5 8.611 3.08 
JSRP1 
Junctional sarcoplasmic reticulum 
protein 1 Q96MG2 8.481 2.41 
KIAA009
0 Uncharacterized protein KIAA0090 Q8N766 34.524 11.84 
LMO7 LIM domain only protein 7 Q8WWI1 0.084 0.04 
MAGT1 Magnesium transporter protein 1 Q9H0U3 0.127 0.09 
MAP4 Microtubule-associated protein 4 E7EVA0 3.428 0.79 
MAPT Microtubule-associated protein tau P10636 6.510 1.84 
MCU 
Calcium uniporter protein, 
mitochondrial Q8NE86 2.658 0.53 
MTATP6 ATP synthase subunit a P00846 0.294 0.03 
MTCO3 Cytochrome c oxidase subunit 3 P00414 0.253 0.05 
MVP Major vault protein Q14764 5.133 1.86 
MYH1 Myosin-1 P12882 0.209 0.05 
NACA 
Nascent polypeptide-associated 
complex subunit alpha E9PAV3 4.244 1.42 
NAP1L4 
Nucleosome assembly protein 1-
like 4 Q99733 127.136 48.51 
NEB Nebulin P20929 4.166 1.18 
NIPSNAP
1 Protein NipSnap homolog 1 Q9BPW8 6.864 2.69 
NME1 Nucleoside diphosphate kinase A Q32Q12 31.955 13.12 
NME1-
NME2 NME1-NME2 readthrough J3KPD9 31.955 13.12 
NME2 Nucleoside diphosphate kinase B P22392 31.955 13.12 
PA2G4 
Proliferation-associated protein 
2G4 Q9UQ80 2.757 0.44 
PADI2 Protein-arginine deiminase type-2 Q9Y2J8 0.646 0.09 
PBXIP1 
Pre-B-cell leukemia transcription 
factor-interacting protein 1 Q96AQ6 2.025 0.43 
PDIA4 Protein disulfide-isomerase A4 P13667 2.524 0.44 
PDLIM5 PDZ and LIM domain protein 5 Q96HC4 3.139 0.56 
145 
 
 
 
PGD 
6-phosphogluconate 
dehydrogenase, decarboxylating P52209 4.370 1.58 
PLOD1 
Procollagen-lysine,2-oxoglutarate 
5-dioxygenase 1 B4DR87 0.490 0.04 
POR 
NADPH--cytochrome P450 
reductase P16435 0.359 0.15 
PRKAB2 
5-AMP-activated protein kinase 
subunit beta-2 O43741 2.629 0.60 
PRKAR2A 
cAMP-dependent protein kinase 
type II-alpha regulatory subunit P13861 3.597 0.88 
PSMA1 Proteasome subunit alpha type-1 P25786 53.646 20.64 
PSMC3 26S protease regulatory subunit 6A P17980 3.605 1.14 
PSMD11 
26S proteasome non-ATPase 
regulatory subunit 11 O00231 5.877 2.23 
PSMD14 
26S proteasome non-ATPase 
regulatory subunit 14 O00487 6.075 2.15 
PSMD2 
26S proteasome non-ATPase 
regulatory subunit 2 Q13200 0.102 0.04 
PSMD7 
26S proteasome non-ATPase 
regulatory subunit 7 P51665 17.159 6.72 
RCN3 Reticulocalbin-3 Q96D15 4.576 1.50 
RPL13A 60S ribosomal protein L13a P40429 0.243 0.07 
RPL15 
60S ribosomal protein 
L15;Ribosomal protein L15 P61313 0.285 0.09 
RPL17 60S ribosomal protein L17 P18621 10.436 4.14 
RPL29 60S ribosomal protein L29 P47914 5.407 1.94 
RPL30 60S ribosomal protein L30 P62888 13.398 5.41 
RPL5 60S ribosomal protein L5 P46777 24.588 9.30 
RPS12 40S ribosomal protein S12 P25398 8.209 3.33 
RPS5 40S ribosomal protein S5 P46782 28.112 10.70 
RPS6 40S ribosomal protein S6 P62753 9.061 3.42 
SCCPDH 
Saccharopine dehydrogenase-like 
oxidoreductase Q8NBX0 0.446 0.15 
SEC11A 
Signal peptidase complex catalytic 
subunit SEC11A H0YK83 0.267 0.09 
SEC23A Protein transport protein Sec23A Q15436 26.210 6.03 
SEPT2 Septin-2 Q15019 15.183 6.14 
SEPT7 Septin-7 Q16181 6.056 2.12 
SFXN3 Sideroflexin-3 Q9BWM7 0.263 0.08 
SLC12A2 Solute carrier family 12 member 2 P55011 0.088 0.04 
SLC12A4 Solute carrier family 12 member 4 Q9UP95 0.299 0.10 
SLC25A1
3 
Calcium-binding mitochondrial 
carrier protein Aralar2 Q9UJS0 0.076 0.04 
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SLC25A5 ADP/ATP translocase 2 P05141 0.142 0.07 
SPCS2 Signal peptidase complex subunit 2 E9PI68 0.204 0.13 
SQRDL 
Sulfide:quinone oxidoreductase, 
mitochondrial Q9Y6N5 3.341 0.72 
ST13 Hsc70-interacting protein P50502 110.492 43.80 
ST13P4 Putative protein FAM10A4 P50502 110.492 43.80 
ST13P5 Putative protein FAM10A5 P50502 110.492 43.80 
STOML2 Stomatin-like protein 2 Q9UJZ1 3.462 1.03 
STT3A 
Dolichyl-diphosphooligosaccharide-
-protein glycosyltransferase subunit 
STT3A P46977 0.211 0.07 
SUCLG1 
Succinyl-CoA ligase [ADP/GDP-
forming] subunit alpha, 
mitochondrial P53597 0.243 0.07 
SYNCRIP 
Heterogeneous nuclear 
ribonucleoprotein Q O60506 1.731 0.25 
TCP1 T-complex protein 1 subunit alpha P17987 0.026 0.00 
TMOD3 Tropomodulin-3 Q9NYL9 0.024 0.01 
TNNT3 Troponin T, fast skeletal muscle P45378 5.713 1.74 
TOR1A Torsin-1A O14656 0.205 0.08 
TP53RK TP53-regulating kinase Q96S44 0.374 0.10 
TPT1 
Translationally-controlled tumor 
protein Q5W0H4 33.050 13.45 
TRAP1 
Heat shock protein 75 kDa, 
mitochondrial Q12931 0.639 0.09 
TRIM72 
Tripartite motif-containing protein 
72 Q6ZMU5 5.590 1.93 
UBA1 
Ubiquitin-like modifier-activating 
enzyme 1 P22314 1.836 0.32 
UGGT1 
UDP-glucose:glycoprotein 
glucosyltransferase 1 Q9NYU2 0.106 0.06 
VAPB 
Vesicle-associated membrane 
protein-associated protein B/C O95292 4.675 1.45 
VDAC2 
Voltage-dependent anion-selective 
channel protein 2 P45880 0.604 0.08 
VIM Vimentin P08670 0.132 0.04 
XIRP1 
Xin actin-binding repeat-containing 
protein 1 Q702N8 0.165 0.02 
YES1 Tyrosine-protein kinase Yes J3QRU1 0.268 0.09 
ZYX Zyxin Q15942 6.145 1.96 
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CHARTER 6. FUTURE WORK 
Protein kinases and their interaction partners have been extensively studied 
due to the importance that kinases catalyze phosphorylation, which is one of the 
most critical protein post-translational modifications that mediated numerous 
molecular functions and biological processes. We successfully profiled the largest 
functional kinome (54 protein kinases) and kinome interactome (616 proteins) in 
human skeletal muscle using activity based enrichment probe and quantitative 
proteomics. The future work of this project would be validate the significantly 
changed protein kinases and their interaction partners by immunoblotting (i.e., 
western blots). Multiple protein identification and quantification techniques would 
robust the results and draw much stronger conclusions.  In addition, comparing 
kinome and kinome interactome in type 2 diabetic patients to those in lean control 
and obese insulin resistant participants will offers insights into type 2 diabetes 
specific mechanisms. 
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ABSTRACT 
HUMAN KINOME IN SKELETAL MUSCLE INSULIN RESISTANCE 
by 
YUE QI 
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Advisor: Dr. Zhengping Yi 
Major: Pharmaceutical Sciences 
Degree: Doctor of Philosophy 
Protein kinases play fundamental roles in regulation of biological processes 
and functions, such as insulin signaling and glucose metabolism. Dysregulation of 
protein kinases may cause impaired cell signaling and human diseases, such as 
metabolic syndrome and type 2 diabetes (T2D). Skeletal muscle is the main site 
responsible for insulin-stimulated glucose disposal, and insulin resistance in 
skeletal muscle is one of the key features of the pathogenesis of T2D. Therefore, 
malfunction of protein kinases and their interaction proteins may contribute to the 
molecular mechanism of insulin resistance in human skeletal muscle. However, no 
large scale profiling study has been reported to investigate the abnormal active 
kinases and their interaction partners that might cause skeletal muscle insulin 
resistance. Here, we present a high throughput platform coupling activity-based 
ATP probes and quantitative proteomics to globally profile functional kinome and 
its interactome in human skeletal muscle in 8 lean healthy and 8 obese insulin 
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resistant participants. We identified 54 active protein kinases in human skeletal 
muscle, which is the largest catalog of experimental determined active kinases to 
date. Twenty-two out of the 54 active kinases displayed a significant change in 
insulin resistant obese subjects, including the protein kinases regulate JNK 
signaling, p38 MAPK signaling, Wnt signaling, AMPK signaling, ERK1/2 signaling 
and mTOR signaling. In addition, we identified 616 functional kinome interaction 
partners in human skeletal muscle, which is the largest human kinome interactome 
to date. Among the 616 interaction partners, 385 has a fold change > 1.5 or <0.67.  
Out of these 385 kinome interaction partners, 135 displayed significantly difference 
between lean heathy and insulin resistant obese subjects. The kinome interactome 
participate in various cell signaling pathways (i.e. diabetes pathway, mTOR 
pathway, insulin signaling pathway, etc.) and biofunctions (i.e. protein synthesis 
and degradation, cytoskeleton dynamics, and apoptosis). In summary, we 
generated the 1st global picture of functional kinome and kinome interactome in 
skeletal muscle in lean heathy individuals, and how it differs in obese insulin 
resistant participants. These results provide novel insights into molecular 
mechanism of skeletal muscle insulin resistance, and may facilitate identifying new 
targets for treating metabolic diseases. 
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